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Abstract

Altered Hemodynamic Control in the Skeletal Muscle Microcirculation in the Metabolic Syndrome:
The Emergence of a new Attractor

Joshua T. Butcher

Peripheral vascular disease is a pathological disease state whereby the peripheral vascular
system becomes progressively limited in its ability to adequately perfuse extremities despite increases in
metabolic demand. One of the primary risk factors for development of peripheral disease is the
Metabolic Syndrome. It is the presentation of three simultaneous comorbidities, with obesity being the
most common denominator in most metabolic syndrome patients, but also including a proinflammatory state, pro-oxidant state, pro-thrombotic state, increased blood pressure, atherogenic
dyslipidemia, or insulin resistance. Currently, the population of the United States is approximately 75%
overweight, obese, or extremely obese and the prevalence of obesity related consequences is rising,
including but not limited to diabetes, cardiovascular disease, and peripheral vascular disease.
Our laboratory has demonstrated that a defining characteristic of metabolic syndrome is
microvascular dysfunction. Increasing evidence has indicated that the mechanisms responsible for
microvascular dysfunction in metabolic syndrome are oxidant stress-based alterations to arachidonic
acid metabolism and increased sensitivity to adrenergic stimulation. However, it remains unclear if the
altered microvascular reactivity that presents with metabolic syndrome plays a role in the perfusion:
demand mismatch that accompanies and defines peripheral vascular disease. This dissertation seeks to
understand the altered hemodynamic control found in metabolic syndrome. It set out to examine:
1.

The effect of altered microvascular reactivity in metabolic syndrome on vascular tone and
performance outcomes.
ii

2. Identify the spatial and temporal alterations to perfusion distribution in metabolic syndrome.
3. Determine the effect of metabolic syndrome on erythrocyte distribution in the microvasculature
and capillaries.
The results of these studies determined that a key contributor to the development, maintenance, and
progression of peripheral vascular disease is microvascular dysfunction. This dysfunction increases the
microvascular perfusion distribution by spatially distinct mechanisms, with adrenergic dysfunction
dominating in larger microvessels and oxidant stress-based increases in thromboxane A2 dominating in
smaller microvessels. Additionally, metabolic syndrome blunts the temporal compensation that would
serve to attenuate the increased perfusion distribution. Combined, the spatial and temporal
impairments to microvasculature serve to alter erythrocyte distribution on a network level in skeletal
muscle. These data shed light on how metabolic syndrome insidiously alters microvascular control of
blood flow, leading to a perfusion: demand mismatch, and ultimately contributing to pathological
disease states like peripheral vascular disease.
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Introduction
Peripheral Vascular Disease
Peripheral vascular disease (PVD) is an insidious pathological disease state that deprives lower
extremities and organs of adequate blood flow due to a narrowing of the supply arteries. Currently within
the United States PVD afflicts between 8-13 million people, but is estimated to be significantly under
diagnosed. PVD patients frequently present with intermittent claudication that occurs during low levels of
exercise (walking, climbing stairs, etc.) but discontinues upon cessation of movement. Patients with a
history of smoking, diabetes, increased blood pressure, obesity, physical inactivity, or high cholesterol
greatly increase their risk of developing PVD, in addition to very high correlations with aging1. The
interventions for PVD are focused upon alleviating the areas with restricted blood flow, and involve
major life alterations to remove risk factors, exercise, drugs, angioplasty, stents, or bypass surgery. Once
diagnosed PVD is largely irreversible barring surgery and possesses a high direct and indirect cost burden
to society2, 3. It becomes clear when position statements are integrated from the American Heart
Association (AHA), Centers for Disease Control (CDC), and American Diabetes Association (ADA) that
one of the major contributing factors to
the development of PVD is structural
and functional alterations to
vasculature4, 5. These alterations
decrease the capacity of the peripheral
vascular system to adequately regulate
blood flow within the skeletal muscle.
The impact of impaired regulation of
blood flow becomes especially evident
in the presence of increased metabolic demand. PVD results in an inability of the system to effectively
1

match blood flow with an increase in metabolic demand, which is illustrated in Figure 1. The functional
outcome of PVD in humans is a progressive acceleration toward decreasing tolerance to exercise,
ultimately leading to disability.
Classically, the perfusion: demand mismatch present in PVD has been characterized by structural
alterations to larger conduit vasculature (e.g., atherosclerotic plaques and lesions)6, 7. However, there is a
growing subset of human subjects that suffer from the symptoms of PVD, but do not exhibit the structural
modifications to larger vasculature. These emerging observations suggest that the underlying perfusion:
demand mismatch seen with development of PVD may be caused by alterations localized to the
microvasculature. Given that structural abnormalities within the microcirculation generally focus on
altered mechanics of the arteriolar wall (which we have demonstrated only impact perfusion at the highest
levels of metabolic demand), or on the density of terminal arterioles and capillaries within the
microvascular network (which also exert their influence primarily with elevated metabolic demand) the
manifestations of PVD at low-moderate metabolic demand may reflect dysfunction within the regulation
of and perfusion distribution in the resistance arterioles8, 9. Obviously, any alteration to normal processes
of vascular reactivity within the resistance arterioles will exert a powerful effect on bulk blood flow and
perfusion distribution and can result in local ischemia and impaired mass transport and exchange. This
would likely be manifested by a variation in the distribution of erythrocytes in the distal microcirculation
and capillary networks.
Purpose
The purpose of this dissertation is to investigate network control of blood flow to determine the
extent to which Metabolic Syndrome-induced microvascular dysfunction alters hemodynamics within
skeletal muscle. It will also endeavor to identify those relevant mechanisms within the microcirculation
that serve as contributors to the negative functional outcomes associated with Metabolic Syndrome
(MetSyn). The obese Zucker rat (OZR) is a model of MetSyn that possesses a recessive leptin receptor
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mutation that leads to chronic hyperphagia. Subsequently, the OZR develops rapid onset obesity, insulin
resistance, dyslipidemia, and moderate hypertension. As the OZR ages, it develops an increasingly severe
myriad of vascular impairments, serves as an appropriate model of MetSyn and development of nonatherosclerotic peripheral vascular disease, and it mimics the leptin resistance induced hyperphagia
observed within the human population. The hypothesis tested in this dissertation is that there is an altered
intramuscular perfusion distribution throughout the skeletal muscle microcirculation in the MetSyn.
Within each chapter of this dissertation is a sub-hypothesis that will address individual aspects of this
hypothesis.
Chapter one hypothesized that oxidant stress-based increases in vascular thromboxane A2
contribute to enhanced myogenic activation and blunted endothelial dependent dilation in both cerebral
and skeletal muscle microvasculature in the OZR. It was designed to examine if vascular tone was
affected when vessels integrated dilator stimuli and pressure induced constriction simultaneously and
whether interventions targeting elevated oxidant stress or elevated TxA2 production would be effective at
restoring normal patterns of reactivity in the OZR. The data from Chapter 1 indicates that MetSyn
induced microvascular dysfunction in the skeletal muscle is heavily dependent on altered arachidonic acid
metabolism. In contrast, MetSyn induced cerebral microvascular dysfunction appears more dependent on
nitric oxide bioavailability. The remainder of this dissertation will focus predominantly on skeletal muscle
microvascular dysfunction.
Chapter two was designed to investigate constrained functional hyperemia in the skeletal muscle
of the OZR. It was hypothesized that the increased resistance to skeletal muscle blood flow was due to a
combined adrenergic constraint and endothelial dysfunction. These data would further support the
relevant mechanisms identified in skeletal muscle in Chapter one, and direct the following two chapters to
focus on high resolution microvascular dysfunction. Chapter three hypothesized that the increased
perfusion heterogeneity observed at bifurcations in the OZR skeletal muscle microvasculature will result
in severe impairments to distal arteriolar blood flow distribution. Further, it identified spatially distinct
3

mechanisms within the microvasculature contributing to the increased perfusion heterogeneity, with alpha
adrenergic dysfunction dominating at the proximal microcirculation and oxidant stress based increases in
TxA2 dominating at the distal microcirculation. It would suggest to us that increased microvascular
perfusion heterogeneity could be a major contributor to the poor muscle performance outcomes described
in Chapter two.
Chapter four hypothesized that the natural compensation for the increased perfusion
heterogeneity at bifurcations in the OZR would be temporal switching. Increased temporal switching
would maintain skeletal muscle performance by serving as a compensatory mechanism to cope with the
increased perfusion heterogeneity. Additionally, this study allowed for the generation of an attractor for
peripheral vascular disease. Chapter 5 hypothesized that the result of the spatial and temporal
impairments iterated across the microcirculatory network would be a negatively impacted erythrocyte
distribution localized to microcirculation and gas exchange vessels. To briefly summarize the
information found in the document below: The MetSyn alters spatial and temporal control of
microvascular hemodynamics, specifically resulting in an altered perfusion distribution throughout the
microvascular network, and serves to embed vascular impairments that contribute to the inability of the
peripheral vascular system to adequately match blood flow with increases in metabolic demand.
Metabolic Syndrome
MetSyn is comprised of many comorbidities that significantly increase the risk for developing
diabetes, stroke, cardiovascular disease (CVD), kidney disease, and PVD. The primary risk factors from
the International Diabetes Federation (IDF), AHA, and CDC are summarized in Table 110. An individual
Table 1: Risk Factors
Central Obesity
(ethnicity dependent)
Triglycerides
HDL Cholesterol
Fasting plasma glucose
Blood pressure

Men
>40 inches

Women
>35 inches

>150mg/dL
<40mg/dL
>100mg/dL
>130/85

>150mg/dL
<50mg/dL
>100mg/dL
>130/85

who is diagnosed with three of the
primary risk factors meets the criteria
for MetSyn. Other measureable factors
considered are a pro-inflammatory state
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(as measured by elevated high sensitivity C-reactive protein, elevated cytokines such as TNF-alpha or IL6, or decreased adiponectin plasma levels) and a pro-thrombotic state (as measured by fibrinolytic factors
like PAI-1 or clotting factors like fibrinogen). Other common contributors include aging, genetics, and an
inactive lifestyle. MetSyn has received a steady increase in interest throughout popular culture as well as
scientific research. This interest is mimicked as the incidence of MetSyn rises throughout the world,
specifically developed countries11.
It is generally associated that obesity is the condition that initiates the development of not only
MetSyn, but also many of the relevant risk factors. There is no universally accepted definition of obesity,
but the frequently referenced standard is body mass index (BMI). Table 2 illustrates the differences in
BMI between the overweight, obese, and extremely obese classifications of individuals. The National
Table 2: Classification
Normal
Overweight
Obese
Extremely Obese

BMI
18-25
>25
>30
>40

Health and Nutrition Examination Surveys (NHANES), a
representative sample of the United States, examined the
prevalence of obese and overweight individuals by gender,

age, and ethnicity from 1999-2010. The percentages of BMI within the adult population of the U.S. in
2010 are shown in Figure 2. It illustrates that two-thirds of the adult population is obese or overweight.
Data analyzed from the last five decades
showed that although overweight
individuals held fairly constant (≈34%),
there was a significant increase in obese
and extremely obese individuals (Figure
3)12. There has been a significant
increase in obesity in the last decade in
children age 2-19, ending with 17% of
children in 2010 being considered
overweight13. Obesity in adult men
5

significantly increased over the 10 year span, and in 2010 ≈35% were considered obese14. Obesity in adult
women held constant across the ten years at ≈35%. A startling statistic was that obesity within the nonHispanic black adults and Hispanic adults stood at ≈49% and ≈39% respectively, significantly higher than
their Caucasian counterparts. Trends suggest that body weight is continuing to rise in children and men,
while women have
leveled off. The rate
of obesity for
children, adolescents,
and adults has
continued to rise. As
of 2010, the
combined
percentages of
overweight, obese,
and extremely obese
individuals for the U.S. adult population is just over 75%15. Of particular importance is that this trend of
obesity appears to be occurring within a younger population, combined with the increasing life span of
adults, it would suggest that an alarming amount of the population within the U.S. will have a significant
risk for developing PVD, particularly at a much younger age. The obesity epidemic, MetSyn, and its
associated risks for cardiovascular disease have only just begun, and this is further reinforced by the
National Institutes of Health (NIH) 2011 Strategic Plan. It includes obesity research targeting the
biological processes and factors that regulate and contribute to body weight control, as well as evaluate
promising strategies and tools for obesity prevention and treatment.
MetSyn cumulatively increases risk for succumbing to a cardiovascular event. One of the many
challenges that understanding MetSyn, and the pathologies it induces, is the broad variety of
6

comorbidities it can contain. While many individuals can be identified clinically as MetSyn patients, it is
not a diagnostic tool. Physicians will target the specific indices of disease as they present. As such, public
health professionals can identify many strong correlations for predicting further progression of MetSyn
pathologies, but identifying causation is difficult. One concrete fact remains, the developed world as a
whole is increasing in weight at a younger age and living longer. If this path is continues unabated, then
an alarming amount of the American population will be significantly predisposed to many cardiovascular
diseases and create an increased economic burden to society.
Vascular Impact of Development of Metabolic Syndrome
The multifaceted components of MetSyn have a varied impact upon the vasculature itself. This
includes decreased endothelial function, increased thrombotic cardiovascular events, plaque
destabilization, increased intima-media wall thickness, and increased vascular stiffness16, 17. It is
becoming apparent that the risk factors involved in MetSyn act synergistically with each other to amplify
alterations to vascular reactivity and structure. The combined outcome is an inability of the peripheral
vascular system to adequately match perfusion with demand.
Vascular tone is the basal level of smooth muscle constriction that a blood vessel experiences at
rest compared to its passive diameter and can vary depending on the tissue bed or organ that the blood
vessel innervates. It is influenced by many factors, including the autonomic nervous system, vasoactive
circulating factors, myogenic activation, shear stress, locally produced vasodilators/constrictors as well as
tissue metabolic demand18. A vessel will integrate each of these influences and alter the blood flow
accordingly. The microvasculature has a large impact on directing blood flow due to it being the primary
site of resistance in the vasculature. The largest portion of resistance throughout the vasculature arises
from arterioles (diameter ≈100 m), the vessels located between the large conduit arteries and capillaries.
The relationship between flow, pressure, and radius is described in equation 1 below:

(Equation 1)
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where Q is flow, R is resistance, and ΔP is change in pressure. Resistance is defined by equation 2:

(Equation 2)
where R is resistance, η is viscosity, and r4 is radius to the fourth power. The combination of Equation 1
and 2 is known as Poiseuille’s Law (Equation 3), and is used to approximate steady laminar flow of a
Newtonian fluid through a tube of fixed length.

(Equation 3)

In the vasculature, the viscosity of blood and the length of blood vessels can be considered
constants, thus the primary director of blood flow is
through altering the diameter of a vessel, and the
influence diameter changes is magnified due to being
raised to the fourth power. The microvasculature
controls blood flow (and thus resistance) by altering
the diameters of blood vessels. The above equation
illustrates the importance of basal vascular tone, and
in general how the microvasculature controls blood
delivery by changing diameter. This dissertation has
focused increased attention on the observation that the
cumulative outcome of spatial and temporal
alterations to the regulation of vascular tone in
MetSyn results in the inability of skeletal muscle
microvasculature to adequately match perfusion:
demand, thus compromising tissue oxygenation. The
imbalance in perfusion:demand matching results in
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ischemia, compromised tissue function, and diminished tissue viability.
Myogenic activity is an intrinsic property of smooth muscle found within blood vessels and is
part of autoregulaton within organ systems that seeks to maintain blood flow despite changes in perfusion
pressure. Specifically, myogenic activity causes smooth muscle cells to contract when pressure is
increased and relax when pressure is decreased. It has been identified as a potent regulator of vascular
tone in several vascular beds, including splanchnic, renal, cardiac, and skeletal muscle, and as such is
important in regulating basal peripheral vascular resistance. It is currently unclear whether the
mechanisms for myogenic activation lie within a mechanical stimulus like a stretch receptor, ion channel,
or cytoskeletal tension, but what is known is that it causes mobilization of calcium and that there is
general agreement that voltage gated calcium channels play an important role18, 19. It has been
demonstrated that the myogenic activity of blood vessels becomes especially relevant in vessels of a
diameter lower than 100 m and that it is endothelial independent, although certainly modulated by
neural, humoral, and tissue factors20, 21.
This dissertation will focus on the types of mechanisms by which MetSyn alters vascular tone
including altered sympathetic activity, increased oxidant stress, and increased production of vascular
thromboxane A2. The first mechanism of altered vascular tone lies within the sympathetic nervous
system. Although the alterations to sympathetic activity in MetSyn are not universally agreed upon, it is
documented in animal models that sympathetic activity is increased in the presence of metabolic
syndrome22. The sympathetic nervous system (SNS) is understood to innervate all of skeletal muscle
vasculature but the primary effect of SNS stimulation appears to constrict the larger blood vessels. It
potentially may be the result of lessening innervation in smaller vessels as smooth muscle lessens toward
capillaries, or perhaps the greater influence of other factors, such as tissue metabolic rate23. The data from
isolated skeletal muscle microvessels and the in situ cremaster preparation have shown an increase in
constriction in the OZR to phenylephrine compared to the lean Zucker rat (LZR) (Figure 4). This
constriction is not mimicked with other potent constrictors, such as angiotensin 2 (Ang 2) or endothelin24.
9

The increased sensitivity to alpha adrenergic stimulation shows comparable results in an in vivo skeletal
muscle artery preparation. This corresponds well with evidence within the human population that
MetSyn increases muscle sympathetic nerve activity (MSNA), although the specific alterations to the
pathway remain unclear25. SNS over-activity is frequently seen in individuals with hypertension, and it
contributes significantly to the initiation, progression, and maintenance of the pathology. A recent study
concluded that deregulation of the SNS is a powerful predictor of the development of MetSyn26.
Another frequently described alteration to vascular tone within the confines of MetSyn is based
on increases in oxidant stress. Reactive oxygen species (ROS) are highly reactive derivatives of oxygen
metabolism that include the superoxide radical, hydroxyl radical, hydrogen peroxide, and include nitric
oxide (NO) and the peroxynitrite radical. ROS are linked to many biochemical processes, including
signaling, growth, and apoptosis. However, in MetSyn the balance of ROS and antioxidants is often
upset, leading to a pro-inflammatory state within the body. In excess, the highly reactive oxidative
products can lead to cellular damage. Research from the Frisbee laboratory, and others, has indicated that
there is an increase in oxidative stress in the OZR, mirroring the human population of MetSyn27.
Classically, this increase in oxidant stress is indicated to be responsible for the decrease in endothelium
derived NO bioavailability. The powerful, yet transient, dilator is scavenged by ROS and is indicated to
be responsible for a significant portion of the impaired dilator capacity of the OZR skeletal muscle
arterioles.
Additionally, there is a growing body of evidence that suggests that the impact of oxidative stress
is two-fold, as alterations to arachidonic acid (AA) metabolism increases the production of vascular TxA2.
Arachidonic acid is a membrane bound phospholipid found within most mammalian cells. It is freed
from the membrane by the enzymes phospholipase A (PLA2), phospholipase C, or phospholipase D. Once
cleaved, the AA can diffuse into the cytoplasmic space and be metabolized. The three primary enzymatic
pathways are through cyclooxygenase (COX), lipoxygenase (LOX), or cytochrome P450 (CYP450). The
prostaglandins are derived via the COX pathway and are the focus of the subsequent research. Once AA
10

is metabolized into PGH2 by COX, it can produce multiple vasoactive compounds that generally will be
classified under two families, the prostacyclins and the thromboxanes (Figure 5).

In health, a balance of constrictors and dilators will be produced, with a functional outcome on
vascular tone being appropriate regulation of blood flow. Research has shown in mice with genetic
dyslipidemia that AA induced dilation is blunted in skeletal muscle arterioles and that vascular TxA2 end
products are increased. However, treatment with an antioxidant or a TxA2 receptor antagonist improved
the altered reactivity and the antioxidant additionally improved the altered AA metabolism28. Additional
research using the OZR, a model of metabolic syndrome, suggested that the impaired dilator response to
reduced oxygen tension could be a result of not only a decrease in prostacyclin production, but also an
increase in vascular TxA2. This data suggests that the increase in oxidant stress goes beyond the inhibition
of a vasodilator. By simultaneously scavenging NO and shifting AA metabolism from prostacyclin to
TxA2, the microvasculature predominantly experiences a greater tonic vasoconstrictor force as well as
counteracting the effect of vasodilators.
11

Clinical Significance and Miscellaneous
The significance of this research has far reaching albeit indirect clinical implications. The most
obvious is that treatment of PVD should not just address bulk blood flow impairments, which is
classically what physicians address upon a diagnosis of PVD, but also microvascular dysfunction for real
improvement to performance outcomes. The most difficult aspect of this, at the moment, would be
proving microvascular dysfunction directly in human beings, given that the level of resolution for in vivo
human blood flow is limited by technology. Additionally, while altered AA metabolism has long been
suspected in many pathological states, and has long been a target for therapeutics, an effective target for
the altered production of TxA2 has not been demonstrated. Importantly, while the first chapter of this
dissertation includes cerebral microvasculature but for the remainder focused on skeletal muscle
microvasculature, the impact of altered cerebral blow flow on stroke, dementia, Alzheimer’s, and other
brain pathologies cannot be underestimated. One of the effective and frequently prescribed treatments for
PVD is anticoagulants. Our experiments utilize a heparinized carotid catheter for the prevention of blood
clots with the monitoring of mean arterial pressure. While this could potentially serve as a confounding
variable in our experimental design, the concentration of heparin the animal is exposed to is well below
the treatment limits. This is further verified by blood clotting during animal experimentation, of which no
impairment is observed. It is worth noting that the vessels being studied in the in vivo and in situ studies
have survived the progressive loss of microvessel density frequency observed in OZR of this age, and it is
estimated that approximately 20-30% of vessels have undergone rarefaction.
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ABSTRACT
Objective: To use the obese Zucker rat (OZR) model of the metabolic syndrome to determine the impact
of dilator stimuli on myogenic activation (MA) of gracilis arterioles (GA) and middle cerebral arteries
(MCA). We tested the hypothesis that increased oxidant stress and thromboxane A2 (TxA2) exacerbate
MA, and prevent its blunting with dilator stimuli, in OZR. Methods: GA/MCA from OZR and lean
Zucker rats (LZR) were pressurized ex vivo. MA was determined under control conditions and following
challenge with acetylcholine, hypoxia and adenosine. Responses were also evaluated after pre-treatment
with TEMPOL (antioxidant) and SQ-29548 (PGH2/TxA2 receptor antagonist).

Results: MA was

increased (and dilator responses decreased) in GA/MCA from OZR, dependent on the endothelium and
ROS. In GA, the impact of ROS on MA and dilator effects was largely via TxA 2, while in MCA, this
appeared was more dependent on NO bioavailability. Intrinsic responses of GA/MCA to carbacyclin,
U46619, and NO donors were similar between strains. Conclusions: A developing ROS-based
endothelial dysfunction in MCA and GA of OZR contributes to an enhanced MA of these vessels. While
treatment of GA/MCA with TEMPOL attenuates MA in OZR, the mechanistic contributors to altered
MA, distal to ROS, differ between the two resistance vessels.

Key Words: regulation of vascular tone, rodent models of metabolic syndrome, peripheral resistance,
microcirculation

List of Abbreviations: Gracilis Arteriole (GA), Middle Cerebral Artery (MCA), Thromboxane A2 (TxA2),
Reactive Oxygen Species (ROS)
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INTRODUCTION
The metabolic syndrome, also referred to as insulin resistance syndrome or cardiometabolic syndrome,
was fully articulated by Reaven in 1988 (25) but has since been more stringently defined with its
continual increases in both incidence and prevalence (1, 4, 6, 7). According to the International Diabetes
Federation (IDF), a clinical diagnosis of metabolic syndrome is made in patients that have central
(abdominal) obesity, and two of the following co-morbidities: dyslipidemia, hypertension and impaired
glycemic control (1).

With these systemic pathologies, a companion pro-inflammatory and pro-

thrombotic state is also commonly present (16, 20, 22).

The most significant health outcome of these

states is that they severely increase the risk for developing peripheral vascular disease (PVD) (4, 16, 20),
a condition characterized by an inability of the vasculature to effectively match blood perfusion with local
tissue/organ metabolic demand. As the regulation of vascular tone and the ability to effectively integrate
multiple vasoactive processes is a critical component of blood flow regulation, alterations to the normal
patterns of vascular reactivity could severely compromise perfusion:demand matching.
The obese Zucker rat (OZR: fa/fa) is an excellent model for the development of the metabolic syndrome
and the associated negative vascular outcomes in humans. It possesses a recessive mutation leading to
leptin receptor dysfunction (3, 29), causing a chronic hyperphagic state (17), which results in rapid-onset
obesity. By 17 weeks of age, the OZR is severely obese, with the combined presentation of profound
insulin resistance, dyslipidemia, and moderate hypertension (17, 26); a combination of pathologies that
parallels metabolic syndrome in humans.
Full manifestation of the metabolic syndrome in OZR has been well documented to be associated with
significant alterations to vascular reactivity (8, 15, 28). It has previously been shown that myogenic
activation of both cerebral (24) and skeletal muscle (10) resistance vessels is enhanced, although there is
no consistent understanding of the mechanistic underpinnings of this elevated responsiveness to
intralumenal pressure. However, in ex vivo skeletal muscle and cerebral resistance arteries/arterioles from
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OZR, there is an impaired response to multiple endothelium-dependent dilator stimuli (8, 9, 24, 28), and
elevated levels of vascular oxidant stress can cause an increased production of the potent vasoconstrictor
metabolite thromboxane A2 (TxA2; refs: 15, 21, 28). The extent to which impaired dilator responses and
elevated production of constrictor metabolites can impact myogenic activation remains unclear.
Our previous work has suggested that the enhanced myogenic activation of skeletal muscle and cerebral
resistance vessels in OZR may not reflect a common mechanistic basis (10, 24). Further, it is entirely
unclear how myogenic activation in these critically important sites of vascular resistance integrates
stimuli from intralumenal pressure and dilator influences to produce a change in diameter. As such, the
general purpose of the present study is to determine the fundamental mechanisms of altered myogenic
activation between these vascular beds, how this may be impacted by challenge with dilator stimuli, and if
identified alterations are due to a consistent, system-wide effect. The general hypothesis is that oxidant
stress-based increases in generation of vascular thromboxane A2 will contribute to enhanced myogenic
activation and blunted endothelium-dependent dilation in both cerebral and skeletal muscle resistance
vessels.
MATERIALS AND METHODS
Animals: Male lean Zucker (LZR; n=32) and obese (OZR; n=35) rats (Harlan, Indianapolis, IN) of ~17
weeks age were used for all experiments. Animals were housed and fed standard chow and tap water ad
libitum at the West Virginia University HSC and all protocols received prior approval from the
Institutional Animal Care and Use Committee.

Table 1 summarizes the baseline characteristics of

animals used in the present study and clearly demonstrates the systemic pathologies associated with the
metabolic syndrome.

Following an overnight fast, all animals were anesthetized with pentobarbital

sodium (50 mg/kg; i.p.) and received tracheal intubation to facilitate maintenance of a patent airway. All
animals also received cannulation of both a carotid artery for blood pressure recording and a jugular vein
for infusion of supplemental anesthetic (as needed) and the collection of blood samples. Venous blood
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samples were analyzed for glucose (Freestyle Lite, Abbott, Alameda, CA), while the plasma components
were analyzed for insulin concentrations (Millipore; Billerica, MA) as well as cholesterol/triglyceride levels
(Wako Diagnostics; Richmond, VA), and nitrotyrosine (Oxis International; Foster City, CA).

Unless

otherwise noted, all drugs and chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Preparation of Isolated Microvessels: After the initial surgery (above), a gracilis muscle resistance
arteriole (GA) was surgically removed from the anesthetized animal and prepared for video microscopy,
as described previously (5). Briefly, the arteriole was placed in a heated (37 oC) bath, doubly-cannulated
with glass micropipettes and secured with silk suture. The vessel was then perfused and superfused with
a physiological salt solution (PSS) equilibrated with 21% O2, 5% CO2, balance N2.

Immediately

following removal of the GA from the animal, the rat was humanely euthanized and the brain was rapidly
removed from the skull case, placed in chilled PSS (~4oC), and the middle cerebral artery (MCA) was
surgically removed from the base of the brain. The MCA was then doubly-cannulated and prepared in an
identical manner as described for the GA. Both the MCA and the GA were allowed to equilibrate for at
least 45 minutes at an intralumenal pressure of ~80% of the individual animal’s mean arterial pressure
(equilibration pressure).

Vessel dimensions under control conditions and in response to imposed

challenge were obtained under pressurized, zero flow conditions using video microscopy and an onscreen video-micrometer (5).
Changes in vessel diameter (myogenic activation) were measured following random changes in
intralumenal pressure between 60 mmHg and 140 mmHg in 20 mmHg increments.

After the initial

assessment of myogenic responses, dilator reactivity was assessed at each level of intralumenal pressure
following challenge with hypoxia (20 minutes), acetylcholine (10-6 M), and adenosine (10-6 M). For the
purposes of the present study, hypoxia was defined as a change in PO2 of the superfusate/perfusate PSS
from ~135 mmHg [21% O2, 5% CO2, balance N2 in the equilibration gas] to ~45 mmHg [0% O2, 5% CO2,
balance N2 in the equilibration gas]). These oxygen pressures have been previously validated with O2
microelectrodes in the vessel chamber (19). Upon completion of data collection under untreated control
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conditions (above), both MCA and GA were treated with either the antioxidant TEMPOL (10 -4 M) or the
PGH2/TxA2 receptor antagonist SQ-29548 (10-5M) and at least 30 minutes was allowed for incubation.
Following the incubation period, myogenic activation and dilator reactivity to the three stimuli at each
level of intralumenal pressure was determined as described above. In an additional series of experiments,
following the determination of responses under control conditions, the endothelium of both MCA and GA
was denuded by passage of air boli through the vessel lumen (19) and the mechanical responses to
intralumenal pressure and dilator stimuli were repeated.
A final series of experiments was performed to determine the responses of isolated GA and MCA
from both LZR and OZR, at the equilibration pressures, in response to increasing concentrations of
carbacyclin (10-12 – 10-8 M; a stable PGI2 analog; Enzo Life Sciences, Farmingdale, NY), U46619 (10-12 –
10-8 M; a stable TxA2 analog; Enzo Life Sciences, Farmingdale, NY), and sodium nitroprusside (10 -10 –
10-6 M). These experiments were performed to determine if the development of the metabolic syndrome
had a significant impact on the intrinsic responses of the GA or MCA in response to the major relevant
vasoactive metabolites under interrogation in the present study.
Data and Statistical Analysis: All data are presented as mean±SE. Active tone of individual vessels at
the equilibration pressure was calculated as (D/Dmax)100, where D is the diameter increase from rest
in response to Ca2+-free PSS, and Dmax is the maximum diameter measured at the equilibration pressure in
Ca2+-free PSS. Curves describing myogenic activation under any of the imposed conditions were fit with
linear regression equations:
(mmHg),

=y-intercept, and

; where

=intralumenal pressure

=the slope of myogenic activation of the vessel. All other statistical

analyses utilized Student’s t-test or analysis of variance (ANOVA) with Student-Newman-Keuls test
post-hoc. Statistical significance is represented by p< 0.05.
RESULTS

20

The baseline characteristics of LZR and OZR used in the present study are summarized in Table 1. At 17
weeks of age, OZR demonstrate significant increases in body mass, moderately elevated blood pressure,
increased insulin resistance, and systemic oxidant stress. Table 2 summarizes the diameters of the vessels
in this study from both LZR and OZR, at the equilibration pressures, under the different treatment groups
in the present study.

In GA, there were few differences between LZR and OZR, although the passive

diameter of the vessel at the equilibration pressure was reduced in the obese animals. In contrast, MCAs
manifested a significant increase in basal tone at the equilibration pressure, but exhibited no reduction in
passive diameter.
Figure 1 summarizes myogenic activation of isolated GA (Panel A) and MCA (Panel B) from LZR and
OZR in response to elevated intralumenal pressure.

In both GA and MCA, the pressure-induced

vasoconstriction was significantly elevated in vessels from OZR as compared to responses in LZR. The
impact of endothelium denudation is presented in Panels C (for GA) and D (for MCA). Removal of the
vascular endothelium abolished almost all of the differences in myogenic activation of either GA or MCA
between LZR and OZR.
The impact of pre-treatment of vessels with the antioxidant TEMPOL or the PGH2/TxA2 receptor
antagonist SQ-29548 on myogenic activation is presented in Figure 2. In GA from OZR, pretreatment
with either TEMPOL (Panel A) or SQ-29548 (Panel B) significantly reduced the slope of the myogenic
activation curve as compared to responses in untreated control conditions. In contrast, while TEMPOL
exerted a similar effect on myogenic activation in MCA of OZR as compared to that in GA (Panel C),
treatment with SQ-29548 did not significantly impact myogenic activation (Panel D).

Combined

treatment with both TEMPOL and SQ-29548 did not significantly reduce the slope of myogenic
activation beyond that determined for either agent alone (data not shown).
The impact of hypoxia on myogenic activation of GA and MCA is summarized in Figure 3. In GA from
LZR, imposition of hypoxia increased arteriolar diameter at the equilibration pressure and blunted
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myogenic activation.

In contrast, challenge with hypoxia had no significant impact on myogenic

activation of GA from OZR (Panel A). Pre-treatment with either TEMPOL (Panel B) or SQ-29548
(Panel C) altered this response in GA from OZR, causing not only an increased diameter at the

the pressure-induced constrictor response. Combined treatment with both TEMPOL and SQ-29548 did
not result in any significant additive effect beyond that determined for either application alone (data not
shown).

The impact of hypoxia alone (Panel D) and hypoxia following pre-treatment with TEMPOL

(Panel E) on myogenic activation of MCA were similar to that for GA from OZR. Hypoxia alone did not
significantly impact the enhanced pressure-induced constriction from MCA in OZR, although pretreatment with TEMPOL not only increased the vessel diameter at the equilibration pressure, it also
blunted to slope of the myogenic activation curve to levels that were comparable to that in LZR. In
contrast, pre-treatment with SQ-29548 did not significantly impact the relationship of myogenic
activation and hypoxia in MCA from OZR (Panel F). As with GA, treatment of MCA with both
TEMPOL and SQ-29548 did not alter the response as compared to the maximum improvement following
single treatment (data not shown).
The impact of acetylcholine on myogenic activation of GA and MCA from LZR and OZR is presented in
Figure 4. In GA from OZR, treatment with acetylcholine resulted in a modest dilation at the equilibration
pressure, but did not significantly impact the slope of the myogenic activation curve (Panel A). While
pre-treatment of GA from OZR with TEMPOL resulted in both an increased dilation at the equilibration
pressure and a shifted slope coefficient for myogenic activation to levels that were not different from that
in LZR (Panel B), treatment with SQ-29548 (Panel C) demonstrated no identifiable improvements to
either the diameter at the equilibration pressure or the slope of myogenic activation.

In MCA,

acetylcholine increased the vessel diameter at the equilibration pressure in LZR, while also causing a
significant shift in slope. In contrast, challenge with acetylcholine resulted in directionally similar,
although less striking effect on myogenic activation of MCA from OZR (Panel D). Pre-treatment of
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MCA from OZR with TEMPOL (+acetylcholine) reduced the severity of myogenic activation to a slope
coefficient that was actually more positive than that determined under control conditions in LZR (Panel
E).

Treatment of MCA from OZR with SQ-29548 (Panel F) did not elicit a significant impact on

myogenic activation following treatment with acetylcholine beyond that identified in for acetylcholine
treatment alone (Panel D).
The mechanical responses of GA and MCA from LZR and OZR to increasing concentration of
carbacyclin (Panel A), U46619 (Panel B) and sodium nitroprusside (Panel C) are summarized in Figure 5.
For carbacyclin and sodium nitroprusside, dilator responses of GA and MCA in response to increasing
concentrations of the agonist were brisk throughout the concentration range, with no significant
differences between vessels from LZR and OZR. Similarly, constrictor responses to U46619, while brisk
and extensive for both GA and MCA were not significantly different between LZR and OZR.
Figure 6 presents myogenic activation of GA and MCA from LZR and OZR in response to the presence
of elevated adenosine (10-6M). In both GA (Panel A) and MCA (Panel B), the presence of adenosine
significantly increased vessel diameter at the respective equilibration pressures and blunted the severity of
the enhanced myogenic activation.
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DISCUSSION
Systemic PVD is an insidious disease that is characterized by an inability of the tissue/organ vasculature
to adequately match local metabolic demand with perfusion. While there can be several contributors to
this outcome, alterations to the control of vascular tone within resistance vessels represents a dominant
factor. The OZR has proven to be an excellent model for the human progression to non-atherosclerotic
PVD as the metabolic syndrome can alter vascular reactivity in the absence of plaque/lesion development
(2). However, one of the challenges of studying any disease with a functional outcome on the regulation
of blood flow and its intra-organ distribution is an understanding of how resistance arteries/arterioles
integrate multiple inputs to produce an appropriate response. It has been established that OZR possess an
enhanced myogenic activation in response to intralumenal pressure in both the skeletal muscle (10) and
cerebral circulation (24). It has also been demonstrated that the chronic increase in vascular oxidant
stress in OZR results in a shift in arachidonic acid metabolism, increasing production of vascular TxA 2
over levels determined in LZR (15). Further, it has been demonstrated that this this process can have a
marked deleterious impact on intra-organ distribution of perfusion via alterations to the integrated
regulation of vascular tone in skeletal muscle (11).

From this, the question arises as to how vascular

myogenic activation within the metabolic syndrome is impacted by changes in dilator stimuli and whether
interventions targeting elevated oxidant stress or elevated TxA2 production are effective at restoring
normal patterns of reactivity between myogenic activation and interactions with dilator influences.
The initial observation from this study is that pressure-induced constriction is increased in both GA and
MCA from OZR as compared to LZR, supporting previous observations (10, 24). Removal of the
vascular endothelium largely abolished differences in myogenic activation between OZR and LZR,
suggesting that the endothelium may represent the primary contributor to differences between the strains.
Previous evidence using OZR (9, 10, 15, 28) and similar models (2) suggests that two endothelium-
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dependent mechanisms, both of which stem from a chronically elevated vascular oxidant stress, may be
responsible for the endothelial influence on myogenic activation: a reduction to vascular NO
bioavailability via increased ROS scavenging and a shift in arachidonic acid metabolism toward
production of the vasoconstrictor TxA2. This interpretation is supported by data presented in Figure 2,
where pre-treatment of GA or MCA of OZR with the TEMPOL shifted myogenic activation to levels that
were comparable to those determined in LZR. However, while is it clear that ROS plays a role in
myogenic activation of both GA and MCA, the role for TxA2 is less consistent. In GA, pre-treatment
with SQ-29548 resulted in a similar effect to that for TEMPOL, a restoration of pressure-induced
constriction to levels in LZR. However, this treatment was largely without effect in MCA from OZR
(Figure 2, Panel D). These data suggest that the contribution of ROS to increased myogenic activation
may not be consistent across vascular beds; being more dependent on TxA 2 in skeletal muscle arterioles,
and more dependent on NO bioavailability in the cerebral circulation.
To further explore the potential contribution of altered arachidonic acid metabolism to the main
observations, the myogenic activation of ex vivo GA and MCA was evaluated under conditions of
hypoxia. While other contributors to this response have been identified, including NO (8, 13, 24) and
-hydroxlases and epoxygenases (8, 12, 13), in both GA
and MCA, this has been demonstrated to be a dilator response that is largely-dependent on the production
of PGI2 from arachidonic acid (15, 19, 21). As shown in Figure 3, imposition of hypoxia alone had only
mild effects on myogenic activation in either GA or MCA from OZR.

This was not surprising, as

hypoxic dilation of resistance vessels is impaired in OZR, in large measure due to a reduction in mediator
bioavailability and an increased production of TxA2 (8, 15, 24). However, when pre-treated with
TEMPOL, the impact of hypoxia became much more pronounced, significantly blunting the slope of
myogenic activation in vessels from OZR. This observation clearly suggests that the increased vascular
oxidant stress is contributing to not just the enhanced myogenic activation of GA and MCA, but also to
the inability of hypoxia to blunt the enhanced pressure-induced constriction in vessels from OZR.

An
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intriguing disparity exists when this is extended to the potential role for TxA2, as pre-treatment with SQ29548 resulted in an identical outcome as that for TEMPOL pre-treatment in GA from OZR (Figure 3,
Panel C), while having a very limited effect in MCA (Figure 3, Panel F). These data clearly suggest that
the impact of ROS on myogenic activation in GA from OZR, and the relative inability of hypoxia to blunt
the pressure-induced constriction in these vessels, may be mediated predominantly through the production
and actions of TxA2. In contrast, while the effects of ROS and the impact of hypoxia on myogenic
activation of MCA from OZR are qualitatively similar in MCA, the contribution of TxA 2 to this process
may be considerably lower.
Pursuant to this, we switched to a mechanistically different dilator, acetylcholine, which is largely NOdependent in the rat vasculature (27). While the impact of acetylcholine on myogenic activation of GA
and MCA from OZR was comparable to that for hypoxia, and pre-treatment with TEMPOL increased the
impact of the stimulus on myogenic activation of both GA and MCA, pre-treatment with SQ-29548 had
no identifiable impact on myogenic activation of either vessel (+ acetylcholine; Figure 4, Panels C and F).
Based on previous data regarding the mechanistic pathways for acetylcholine and the results presented
above, these data provide additional support for the concept of a divergence in ROS-dependent
contributors to the enhanced myogenic activation of GA and MCA from OZR.
One question that arises from the results of the present study is the intrinsic sensitivity of GA and MCA
from LZR and OZR in response to PGI2 (carbacyclin), TxA2 (U46619) and nitric oxide, and whether this
changes with the evolution of the metabolic syndrome. However, the data presented in Figure 5 indicate
that vascular responsiveness to these three metabolites remains robust and does not demonstrate any
consistent alteration in this model. As such, it is plausible at this time to ascribe differences in vascular
responses to myogenic stimulation and dilator influences as an issue of mediator bioavailability, rather
than one of vascular responsiveness.
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Used as a proxy variable for elevated metabolic demand, the impact of elevated adenosine (10 -6 M) on
myogenic activation of GA and MCA from OZR reveals an intriguing relationship. In skeletal muscle
arteriole of OZR, elevated adenosine attenuated the severity of the pressure-induced vasoconstriction,
resulting in a response that was similar to that determined in GA from LZR. One would predict that this
would be an appropriate response of the resistance vasculature in response to elevated metabolic demand
– a shift in the overall setting of myogenic activation, such that flow regulation can still be maintained,
although at a lower overall resistance. However, given that this ‘adenosine-treated’ response remains
blunted below that in GA from LZR treated with adenosine, altered myogenic activation in GA of OZR
may still represent a contributor to reduced bulk perfusion and altered perfusion distribution with elevated
metabolic demand (14). In contrast, application of adenosine to MCA resulted in a very comparable
blunting of myogenic activation in vessels from both LZR and OZR. Speculatively, these observations
suggest that the ability of local metabolic demand in the brain may be more able to override the increased
pressure-induced constriction in the cerebral resistance vessels of OZR than in the skeletal muscle
microcirculation.

However, the extent to which this may serve as a protective mechanism under

conditions of cerebral ischemia or hypoxia in OZR, where stroke severity may be enhanced (22) remains
unknown at this time.
PERSPECTIVES
With the development of the metabolic syndrome in this model, an increased pressure-induced
constriction of resistance vessels develops in both the skeletal muscle and cerebral circulation. While the
genesis of this increased myogenic activation for both vessels appears to lie within an elevation in
vascular oxidant stress, the increased response in skeletal muscle vessels appears to reflect an increased
contribution from the production of TxA2, while responses in the cerebral circulation appear to reflect a
loss of dilator metabolite bioavailability. Importantly, the ability of local metabolic demand to override
myogenic activation appears to still be present in both tissues, and may be fully intact in the brain. While
this may reflect a protective mechanism in the brain versus skeletal muscle, further interrogation into the
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functional impact of these differences on organ perfusion as well as therapeutic interventions against the
increased myogenic activation should keep this in mind.
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Table 1. Baseline characteristics of 17 week-old LZR and OZR used in the present study. * p<0.05
versus LZR.
LZR (n=30)

OZR (n=34)

Mass (g)

34411

66912*

MAP (mmHg)
[Glucose]plasma (mg/dl)
[Insulin]plasma (ng/ml)
[Nitrotyrosine]plasma (ng/ml)

106±6
105±11
1.4±0.2
15±5

126±5*
181±10*
8.5±1.2*
45±8*
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Table 2. Inner diameter (at the equilibration pressure) of gracilis arterioles (GA) and middle cerebral
arteries (MCA) of LZR and OZR used in the present study. Data in parentheses represents % active tone.
* p<0.05 versus LZR.

Gracilis Arteriole

Middle Cerebral Artery

LZR

OZR

LZR

OZR

1045 (44±4%)

965 (43±3%)

121±4 (43±4%)

105±5 (46±4%)*

-Endothelium
+Hypoxia
+SQ-29548
+TEMPOL
+Acetylcholine

101±4
118±4
107±4
104±5
115±5

100±5
100±5
102±4
105±4
101±5

118±5
138±4
120±5
116±5
133±5

114±4
115±5*
109±4
113±5
112±4

+Adenosine
Ca2+-free PSS (Passive)

118±4
184±5

109±5
169±5*

129±4
204±4

119±5
194±5

Control
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FIGURE LEGENDS
Figure 1: Data describing myogenic activation of isolated gracilis muscle arterioles (Panels A and C; n=5
for both) and middle cerebral arteries (Panels B and D; n=5-6 for both) from LZR and OZR in response to
increased intralumenal pressure. Data, presented as mean±SE, are presented for vessels under control
conditions (Panels A and B) and following removal of the endothelium (Panels
coefficients describing the curve of myogenic activation are presented in the inset legend. * p<0.05 vs.
LZR-Control; † p<0.05 vs.OZR-Control.
Figure 2: Data describing myogenic activation of isolated gracilis muscle arterioles (Panels A and B;
n=5-7 for both) and middle cerebral arteries (Panels C and D; n=6 for both) from LZR and OZR in
response to increased intralumenal pressure. Data, presented as mean±SE, are presented for vessels under
control conditions and following pre-treatment of the vessels with either TEMPOL (10-4M) or the
PGH2/TxA2 receptor antagonist SQ-29548 (10-5
myogenic activation are presented in the inset legend.

* p<0.05 vs. LZR-Control; † p<0.05 vs.OZR-

Control.
Figure 3: Data describing myogenic activation of isolated gracilis muscle arterioles (Panels A-C; n=5-6
for all) and middle cerebral arteries (Panels D-F; n=5 for all) from LZR and OZR in response to increased
intralumenal pressure. Data, presented as mean±SE, are presented for vessels under control conditions,
following imposition of hypoxia and following pre-treatment of the hypoxic vessels with either TEMPOL
(10-4M) or the PGH2/TxA2 receptor antagonist SQ-29548 (10-5
curve of myogenic activation are presented in the inset legend.

* p<0.05 vs. LZR-Control; † p<0.05

vs.OZR-Control; ‡ p<0.05 vs. OZR-Hypoxia.
Figure 4: Data describing myogenic activation of isolated gracilis muscle arterioles (Panels A-C; n=5 for
all) and middle cerebral arteries (Panels D-F; n=5-6 for all) from LZR and OZR in response to increased
intralumenal pressure. Data, presented as mean±SE, are presented for vessels under control conditions,
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following challenge with acetylcholine (10-6 M) and following pre-treatment of the acetylcholinechallenged vessels with either TEMPOL (10-4M) or the PGH2/TxA2 receptor antagonist SQ-29548 (105

* p<0.05 vs. LZR-Control; † p<0.05 vs.OZR-Control; ‡ p<0.05 vs. OZR-Hypoxia.
Figure 5: Data describing the mechanical responses of isolated gracilis muscle arterioles and middle
cerebral arteries from LZR and OZR in response to increased concentrations of carbacyclin (Panel A; n=5
for all), U46619 (Panel B; n=5 for all) and sodium nitroprusside (Panel C; n=5 for all). Data, presented as
mean±SE, are presented for vessels under control conditions, at their equilibrium pressure. There were no
significant differences in the mechanical responses of GA or MCA between LZR and OZR for the three
agonists.
Figure 6: Data describing myogenic activation of isolated gracilis muscle arterioles (Panel A; n=5) and
middle cerebral arteries (Panel B; n=5) from LZR and OZR in response to increased intralumenal
pressure. Data, presented as mean±SE, are presented for vessels under control conditions and following
challenge with adenosine (10-6 M). * p<0.05 vs. LZR-Control; † p<0.05 vs.OZR-Control.
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Conceptual Framework:
The first chapter of this dissertation is entitled “Differential Impact of Dilator Stimuli on
Increased Myogenic activation of Cerebral and Skeletal Muscle Resistance Arterioles in Obese Zucker
Rats”. This paper is part of the foundational work that illustrates the potent impact of MetSyn on vascular
tone. Myogenic activation is a dominant factor controlling vascular tone because it is part of the intrinsic
vascular control within vessels that maintains a constant blood supply despite changes in perfusion
pressure. It has been previously shown that myogenic activation is increased in vascular beds in the OZR
compared to the LZR, although the mechanism for this increase had not been elucidated. This paper
sought to examine if the increase in oxidant stress and/or altered AA metabolism were appropriate
interventions to treat the increased myogenic activation and how this will integrate with other dilator
stimuli. The data confirmed the increased myogenic activation seen previously in the OZR in both
skeletal muscle and cerebral vasculature, and that the changes in myogenic activation appear to largely be
endothelial dependent. It also revealed that the impact of ROS was primarily through the action of TxA2.
In the isolated microvessel preparation the skeletal muscle gracilis arteriole showed a restoration of
myogenic activation with treatment of TEMPOL, a ROS scavenger, and a similar response to SQ-29548,
a TxA2 receptor antagonist. Further experiments integrating dilator conditions (hypoxia, acetylcholine,
and adenosine) with myogenic activation revealed an attenuated dilator response compared to the LZR. In
skeletal muscle, a large portion of the impaired dilator response is oxidant stress-induced as well as
mediated through the production and action of TxA2. A key part of these data showed that the increased
myogenic activation seen in the OZR was capable of blunting the adenosine response. Adenosine is often
used as a mimic for an increase in metabolic demand, and this indicates that increased myogenic
activation contributes to altered vascular responses even during increased levels of metabolic demand.
This chapter lays the groundwork for suggesting that the microvasculature in the OZR is compromised in
its ability to integrate vasoactive compounds and adequately regulate blood flow.
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ABSTRACT
The metabolic syndrome is associated with elevated peripheral vascular disease risk, characterized by
mismatched blood flow delivery/distribution and local metabolism. The obese Zucker rat (OZR) model
of the metabolic syndrome exhibits myriad vascular impairments, although their integrated impact on
functional hyperemia remains unclear. In this study, arterial pressor responses and skeletal muscle
perfusion were assessed in lean Zucker rats (LZR) and OZR during adrenergic stimulation
(phenylephrine),

challenge

with

thromboxane

(U46619)

and

endothelium-dependent

dilation

(methacholine). OZR were hypertensive versus LZR, but this was abolished by adrenoreceptor blockade
(phentolamine); pressor responses to U46619 were similar between strains and were abolished by
blockade with the PGH2/TxA2 receptor antagonist, SQ-29548. Depressor reactivity to methacholine was
impaired in OZR, but was improved by antioxidant treatment (TEMPOL). Across levels of metabolic
demand, blood flow to in situ gastrocnemius muscle was restrained by adrenergic constriction in OZR,
although this diminished with increased demand. O2 extraction, reduced in OZR vs. LZR across levels of
metabolic demand, was improved by TEMPOL or SQ-29548; treatment with phentolamine did not impact
extraction and neither TEMPOL nor SQ-29548 improved muscle blood flow in OZR. While VO2 and
muscle performance were consistently reduced in OZR vs. LZR, treatment with all three agents improved
outcomes, while treatment with individual agents was less effective.

These results suggest that

contributions of vascular dysfunction to perfusion, VO2 and muscle performance are spatially distinct,
with adrenergic constriction impacting proximal resistance and endothelial dysfunction impacting distal
microvessel-tissue exchange. Further, these data suggest that increasing skeletal muscle blood flow in
OZR is not sufficient to improve performance, unless distal perfusion inhomogeneities are rectified.

Key Words: rodent models of obesity; skeletal muscle blood flow regulation; models of peripheral
vascular disease; blood flow heterogeneity; vascular dysfunction
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INTRODUCTION
One of the hallmark characteristics in the development of the metabolic syndrome, with its
constituent systemic pathologies of obesity, insulin resistance/type II diabetes mellitus, atherogenic
dyslipidemia and hypertension, is the substantially increased risk for the progressive evolution of
peripheral vascular disease (Cannon, 2008; Ford and Mokdad, 2008; Jones 2008; Obunai et al. 2007).
While this can possess atherosclerotic or non-atherosclerotic elements in its constitution (with distinct
etiological characteristics and outcomes), one of the defining elements of peripheral vascular disease
(PVD) is an evolving inability to effectively match tissue perfusion with local metabolic demand, an
observation routinely demonstrated in both humans and in multiple animal models of the metabolic
syndrome (Baron, 2002; He et al. 1995; Nicholson et al. 1992; Ruiter et al. 2010; Wolfram et al. 2001).
While this has been identified across numerous organs/tissues, we have demonstrated reduced bulk blood
flow to in situ gastrocnemius muscle of the obese Zucker rat (OZR) across ranges of demand from rest to
near maximum metabolic intensity (Frisbee et al. 2009; Frisbee 2005; 2004; 2003).
In OZR, a model of the metabolic syndrome which derives its genesis through chronic
hyperphagia as a result of a severe receptor-based leptin resistance (Guerre-Millo, 1997; Williams et al.
2001), the basic contributing mechanisms underlying the compromised perfusion and hyperemic
responses may include: 1) enhanced adrenergic constrictor reactivity and signaling of skeletal muscle
arterioles (Frisbee, 2004; Naik et al. 2006; Stepp and Frisbee, 2002), 2) a widespread impairment to
arteriolar dilator reactivity, primarily centered around compromised endothelial function (Bouvet et al.
2007; Frisbee et al. 2009; Goodwill et al. 2008; Katakam et al. 2009; Lu et al. 2010), and 3) structural
remodeling of the microvasculature (Bovet et al. 2007; Goodwill et al. 2009; Lu et al. 2010; Stepp et al.
2004), including a reduced wall distensibility of the resistance arterioles (predominantly contributing to
an elevated vascular resistance) and a rarefaction of the distal microvasculature (predominantly
contributing to impairments to mass transport and exchange in the microenvironments). With these
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elements in place, a progressive deterioration in tissue perfusion develops which can, and ultimately does,
negatively impact the ability of the skeletal muscle to resist fatigue (Frisbee, 2006; 2004).
However, recent data suggests that a more complex relationship than has been previously
understood may exist with regard to the linkages between skeletal muscle perfusion and fatigue resistance
within the metabolic syndrome. Specifically, we have recently provided initial evidence that multiple
pathways which derange the normal patterns of skeletal muscle arteriolar reactivity integrate to impair not
only vascular dilation in a metabolic demand-dependent fashion, but also that these can contribute to
perfusion heterogeneity at microvascular bifurcations which could represent a significant contributor to
the compromised ability of microvascular networks to match perfusion to local metabolic demand
(Frisbee et al. 2009).
As a result of these recent observations, there is an immediate need for a more accurate
understanding of the relationships between the perfusion to, and the performance of, skeletal muscle
within the setting of the metabolic syndrome. Given that the metabolic syndrome represents a condition
which strongly predisposes individuals to an elevated risk of PVD, which can be defined as a condition
wherein the perfusion:metabolic demand matching can be substantially impaired, the translational
importance of the thorough understanding of how perfusion and muscle performance are intertwined in
this pathological setting is imperative. The purpose of this study is to thoroughly evaluate functional
outcomes (performance) in skeletal muscle and to provide a framework for future interrogation into the
detailed relationships between vascular function, perfusion and skeletal muscle performance outcomes.
This study was designed to provide a rigorous test of the hypothesis that functional hyperemia is
constrained within skeletal muscle of OZR owing to the combined impact of adrenergic constraint and
endothelial dysfunction, each of which acts to either inappropriately increase, or prevent reductions in, the
resistance to skeletal muscle blood flow over a range of imposed metabolic demand.
MATERIALS AND METHODS
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Animals: 15-17 week old male lean Zucker rats (LZR) and OZR fed standard chow and tap water ad libitum
were used for all experiments. Data describing the baseline characteristics of LZR and OZR in the present
study are presented in Table 1. At this age range, OZR were significantly heavier than age-matched LZR and
also demonstrated fasting (overnight) hyperglycemia, hyperinsulinemia, elevated plasma triglyceride levels
and moderate hypertension. Rats were housed in animal care facility at either the Medical College of
Wisconsin or at the West Virginia University Health Sciences Center, and all protocols received prior
IACUC approval. Rats were anesthetized with injections of sodium pentobarbital (50 mgkg-1 i.p.), and
received tracheal intubation to facilitate maintenance of a patent airway. In all rats a carotid artery and an
external jugular vein were cannulated for determination of arterial pressure and for intravenous infusion of
additional substances as necessary (e.g., anesthetic, heparin, etc.).
Preparation of In Situ Blood-Perfused Skeletal Muscle: In all LZR and OZR, the left gastrocnemius
muscle was isolated in situ (Frisbee, 2003). Briefly, the left leg received a medial incision from the
calcaneus to the femoral triangle, and all muscles, vessels and connective tissue overlaying gastrocnemius
muscle were removed, thus exposing the gastrocnemius muscle, its vascular supply, and the sciatic nerve.
The nerve was isolated and utilized for initiating muscle contraction via a stimulating electrode attached to an
electrical stimulator (Grass SD9). Branches from the femoral artery that did not perfuse the gastrocnemius
muscle directly were ligated or cauterized, depending on size and location. A microcirculation flow probe
(Transonic) was placed around the femoral artery, immediately distal to its origin from the iliac artery, in
order to measure blood flow to the gastrocnemius muscle. As a final step, a 24 gauge angiocatheter was
inserted into the femoral vein to allow for sampling of venous blood from the contracting muscle. The entire
preparation was covered in PSS-soaked gauze and plastic film to minimize evaporative water loss and was
placed under a lamp to maintain temperature at 37C. At this time, heparin (500 U/kg) was infused via the
jugular vein to prevent blood coagulation.
Section One: Arterial Pressor and Hindlimb Perfusion Responses: Following the complete surgical
preparation of the rats, it was necessary to validate the effectiveness of the experimental conditions that were
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to be utilized for the subsequent interrogations of skeletal muscle perfusion and fatigue resistance
1

2

adrenoreceptor

antagonist phentolamine (10 mg/kg; followed by 30 minutes of equilibration), the superoxide dismutase
mimetic 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL; 50 mg/kg; followed by 45 minutes of
equilibration), or the PGH2/TxA2 receptor antagonist SQ-29548 (10 mg/kg; followed by 30 minutes of
equilibration) in order to remove the influences of adrenergic tone, vascular oxidant stress and influence of
vascular sources of TxA2 from the system, respectively. Following treatment of the individual rats with
phentolamine, TEMPOL or SQ-

-dependent nitric oxide donor
2

). Alterations in mean arterial pressure and

femoral artery perfusion were monitored following agonist infusion in order to determine peak responses and
the time to restoration of baseline (pre-treatment) conditions. All infused intravenous doses of drugs were
corrected for differences in circulating blood volume between LZR and OZR at this age (Frisbee, 2006;
Schreihofer et al. 2005).
Section Two: Responses of Contracting In Situ Skeletal Muscle: Following validation of the actions of
phentolamine, TEMPOL or SQ-29548 and restoration of baseline conditions, the gastrocnemius muscle was
stimulated to perform (via the sciatic nerve) bouts of isometric twitch contractions (1, 3, or 5 Hz, 0.4 ms
duration, 5V) for 3 minutes followed by 15 minutes of self-perfused recovery, with arterial pressure and
femoral artery blood flow continuously monitored.

Data were collected under control conditions and

following treatment of the rats with phentolamine, TEMPOL or SQ-29548, as described above.
Data Calculations: In
cannula and femoral vein angiocatheter immediately prior to and following completion of, the muscle
contraction periods. Samples were stored on ice until they were processed for blood gas pressures, percent
oxygen saturation and hemoglobin concentration using a Corning Rapidlab 248 blood gas analyzer. Muscle
perfusion, arterial pressure, and bulk blood flow through the femoral artery were monitored for one minute
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prior to muscle contractions and throughout the contraction period using a Biopac MP150 with
Acqknowledge data acquisition software at a 50Hz sampling frequency. Muscle perfusion and performance
data after three minutes of contraction were normalized to gastrocnemius mass, which was not different
between LZR (2.180.09 g) and OZR (2.060.10 g). Oxygen content within the blood samples was
determined using the following standard equation:
(

[

]

)

(

)

Eq. 1

Where CxO2 and PxO2 represent the total content (ml/dL) or partial pressure of oxygen (mmHg), respectively,
of arterial or venous blood (denoted simply as ‘x’). [Hb] represents hemoglobin concentration within the
blood sample (g/dL); %O2Sat represents the percentage oxygen saturation of the hemoglobin and 1.39 and
0.003 represent constants describing the amounts of bound and dissolved oxygen in blood. Oxygen uptake
across the gastrocnemius muscle was calculated using the Fick equation:
  CaO  CvO 
VO2  Q
2
2

Eq. 2
where VO2 represents oxygen uptake by the gastrocnemius muscle, Q represents femoral artery blood flow
(ml/g/min), and CaO2 and CvO2 represent arterial and venous oxygen content, respectively. Perfusion
resistance across gastrocnemius muscle was calculated as the quotient of mean arterial pressure and muscle
blood flow. Muscle O2 conductance (

) was calculated using Fick’s law of diffusion as a simple

model of O2 flux to the working muscle,
̇

(

)

Eq. 3
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where DmO2 is the diffusing capacity of O2 at the muscle (ml/min/mmHg/mg muscle), P O2 is the mean
capillary PO2 (mmHg), and PmitoO2 is average mitochondrial PO2 (mmHg) (Kurdak et al. 1996; Roca et
al. 1989). Estimation of P O2 is based on a numerical (Bohr) integration procedure that uses a single
parameter for tissue diffusing capacity-to-muscle blood flow ratio (DO2/QT), which is assumed to be
constant along the capillary, where DO2/QT is varied iteratively until the calculated end-capillary PO2
matches the measured venous PO2 to within 0.1 mmHg (Kurdak et al. 1996; Roca et al. 1989). Mean
capillary PO2 (P O2) is then a time-weighted average of all computed PO2 values along the capillary
based on the initial measured arterial and venous PO2 values. Explicit assumptions in making the DmO2
calculation are that, 1) mitochondrial PO2 is negligibly small (i.e. PmitoO2=0 mmHg) at maximal or near
maximal exercise, and that 2) the only explanation of O2 remaining in the femoral venous blood is
diffusion limitation of O2 efflux from the muscle microcirculation (Wagner, 1992).

Accordingly,

perfusional or diffusional shunts are considered negligible, and we only calculate DmO2 for data obtained
at maximal or near maximal exercise (i.e. electrical stimulation at 5 Hz). For all calculations we used
hemoglobin of 15 gm/dL and p50 of 26.8 mmHg.
Statistical Analyses: Statistically significant differences in determined results were assessed using either
Student’s t-test or analysis of variance (ANOVA), with Student-Newman-Keul’s post-hoc test as needed. In
all cases, p<0.05 was taken to reflect statistical significance. All data are presented as mean±SE.
RESULTS
Data describing the animals under investigation in the current study are summarized in Table 1. At
15-17 weeks of age, OZR were dramatically heavier than LZR, and demonstrated a significant impairment to
glycemic control, dyslipidemia, and chronic elevations in vascular oxidant stress.
Figure 1 summarizes the impact of challenge of LZR and OZR with phenylephrine (with and without
pre-treatment with phentolamine) on arterial pressure (Panel A), femoral artery blood flow (Panel B) and
vascular resistance (Panel C) in LZR and OZR. In response to intravenous infusion of the adrenoreceptor
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agonist, mean arterial pressure was significantly increased in both strains, although the magnitude of this
increase was similar between LZR (67±9 mmHg) and OZR (72±12 mmHg). Pre-treatment of animals with
phentolamine reduced arterial pressure in both strains to a similar level and abolished pressor responses to
infused phenylephrine (Panel A).

Femoral artery blood flow in OZR was not significantly different as

compared to LZR under control conditions, and challenge with phenylephrine infusion resulted in a mild, but
variable, reduction in blood flow in both strains (Panel B). Following treatment with phentolamine, femoral
artery blood flow was mildly elevated to similar levels between LZR and OZR, and infusion of
phenylephrine was without effect.

Vascular resistance, elevated in OZR versus LZR under control

conditions, increased significantly in both strains following infusion of phenylephrine (Panel C), although
this response was enhanced in OZR [347±42 mmHg/(ml/g/min)] as compared to LZR [187±30
mmHg/(ml/g/min)].

Treatment of rats with phentolamine lowered resistance in both strains to a similar

level, and blocked the overwhelming majority of the phenylephrine-induced increases in vascular resistance.
The impact of challenging the animal with the TxA2 analog U46619 and the effectiveness of
blockade of the PGH2/TxA2 receptors with SQ-29548 is summarized in Figure 2. Infusion of U46619
increased arterial pressure in both strains, although the magnitude of this effect was very similar between
LZR and OZR (Panel A). While blockade of PGH2/TxA2 receptors had no discernible impact on arterial
pressure, it abolished the pressor response to U46619 in both strains. Infusion of U46619 (either with or
without pre-treatment with SQ-29548) had no impact on bulk blood flow through the femoral artery in either
LZR or OZR (Panel B). Treatment of rats with U46619 resulted in a similar, significant increase in vascular
resistance in both strains, and this response was abolished by pre-treatment with SQ-29548 (Panel C).
Figure 3 presents data describing the impact of both infusion of methacholine and the effects of pretreatment with TEMPOL on arterial pressure (Panel A), femoral artery blood flow (Panel B) and vascular
resistance across the gastrocnemius muscle (Panel C) in LZR and OZR.

In LZR, challenge with

methacholine caused a rapid, significant depressor response that was unaffected by pre-treatment with
TEMPOL. In contrast, infusion of methacholine in OZR did not significantly reduce arterial pressure, while
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pre-treatment of rats with TEMPOL improved the depressor response (Panel A). In preliminary studies,
treatment of either LZR or OZR with the nitric oxide synthase inhibitor L-NAME (100 mg/kg) prevented the
depressor effects of methacholine under any condition (MAP from control in LZR+L-NAME=-3.5±3.6
mmHg; (MAP from control in OZR+L-NAME=+1.4±4.1 mmHg).

In LZR, infusion of methacholine

resulted in an increased femoral artery blood flow, a response not identified in OZR. This effect was not
altered in LZR following pre-treatment with TEMPOL, although it was increased in OZR to the point of
reaching statistical significance (Panel B). Similarly, methacholine infusion resulted in a decreased vascular
resistance in LZR only (with or without TEMPOL treatment), while methacholine-induced reductions in
resistance in OZR were identified following pre-treatment with TEMPOL (Panel C).
The hemodynamic characteristics within gastrocnemius muscle of OZR and LZR under resting
conditions in the present study are summarized in Figure 4. The decreased femoral artery blood flow in OZR
as compared to LZR at rest was eliminated following treatment with phentolamine, although treatment with
either TEMPOL or SQ-29548 was without effect (Panel A). Incorporating arterial pressure, the elevation in
vascular resistance across the gastrocnemius in OZR was corrected following infusion of phentolamine, while
treatment with TEMPOL or SQ-29548 provided no discernible benefit (Panel B). Under resting conditions,
the extraction of oxygen from arterial to venous blood was significantly reduced in OZR versus LZR and, in
contrast to the previous panels, only treatment with TEMPOL or SQ-29548 increased extraction, while
adrenoreceptor blockade was without effect (Panel C). Integrating blood flow and extraction, oxygen uptake
at the gastrocnemius muscle was reduced in OZR versus LZR, and only combined treatment of OZR with all
three agents (phentolamine, TEMPOL and SQ-29548) resulted in a significant improvement to muscle VO2.
In preliminary experiments, treatment of LZR with phentolamine, TEMPOL and/or SQ-29548 failed to elicit
a consistent and/or significant change in the above parameters (data not shown).
In response to 1Hz twitch contractions (Figure 5), the general patterns of the measured outcomes
in the present study were not strikingly different than that presented in Figure 4. Femoral artery blood
flow (Panel A) was reduced and vascular resistance (Panel B) was elevated in OZR versus LZR, and these
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alterations were corrected by pre-treatment with phentolamine (TEMPOL and SQ-29548 having no
consistent measureable impact). In contrast, the reduction in oxygen extraction in OZR versus LZR
(Panel C) was only ameliorated following treatment with either TEMPOL or SQ-29548, with only a
trivial benefit provided by treatment with phentolamine. However, the recovery in VO2 in contracting
gastrocnemius of OZR to levels determined in LZR was only realized following treatment of the animal
with all three agents (Panel D). Muscle fatigue resistance mirrored the patterns in VO 2, with a reduced
tension development after three minutes of contraction in OZR as compared to LZR, and a significant
improvement in contractile performance only occurring following combined treatment of OZR with
phentolamine, TEMPOL and SQ-29548 (Panel E).
Figure 6 summarizes hemodynamic responses in gastrocnemius muscle of LZR and OZR in
response to three minutes of contraction at 3Hz.

While femoral blood flow was lower (Panel A) and

vascular resistance was higher (Panel B) in OZR versus LZR, the ability of phentolamine to restore these
values was less robust than at lower levels of metabolic demand, with neither TEMPOL nor SQ-29548
exerting a discernible impact on these outcomes. In contrast, both TEMPOL and SQ-29548 improved
oxygen extraction (Panel C) and VO2 (Panel D) across gastrocnemius muscle of OZR, while
phentolamine exerted only minimal benefits. Phentolamine was unable to improve skeletal muscle
fatigue resistance in OZR at 3Hz, while both TEMPOL and SQ-29548 did result in a mild improvement
to performance, and combined treatment with all three agents resulted in the greatest improvement in the
ability of the gastrocnemius muscle to maintain developed tension (Panel E).
Data describing the perfusion responses of in situ gastrocnemius muscle of OZR and LZR in
response to 5Hz contraction are summarized in Figure 7. These data appear present a different conceptual
framework, as no employed intervention was able to improve femoral artery blood flow in OZR above
that identified under control conditions (Panel A), and this was paralleled by measures of vascular
resistance, which were very consistent across OZR groups, regardless of intervention (Panel B).
However, treatment with TEMPOL or SQ-29548 improved oxygen extraction (Panel C) to levels similar
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to that in LZR, and VO2 as well (Panel D), although this improvement was constrained by the limits on
normalized muscle O2 conductance (Panel E). Finally, while treatment of OZR with phentolamine was
without effect on muscle fatigue resistance at 5Hz, and both TEMPOL and SQ-29548 resulted in mild
improvements, combined therapy with all agents significantly improved muscle performance in OZR over
that determined under control conditions (Panel F). In preliminary experiments, treatment of LZR with
phentolamine, TEMPOL and/or SQ-29548 failed to elicit a consistent and/or significant change in the above
parameters across levels of metabolic demand (data not shown).

The robust correlative relationships between skeletal muscle O2 conductance and muscle
performance at 5Hz contraction for LZR and OZR under the conditions of the present study are shown in
Figure 8.

DmO2 was a strong correlate of muscle fatigue resistance across LZR and OZR, with an r-

squared value explaining nearly 60% of the variability in the data.
DISCUSSION
One of the most vexing challenges to public health and the quality of life of afflicted individuals
is the insidious progression of peripheral vascular disease (PVD), with its characteristic impairment to
blood flow delivery and the accelerated development of fatigue in those muscles experiencing an
increased metabolic demand (Baron, 2002; Hudlicka and Brown, 2009; Nicholson et al. 1992; Ruiter et
al. 2010; Wolfram et al. 2001). The OZR, with its inherent development of obesity, insulin resistance,
moderate hypertension and hyperlipidemia represents an excellent model of non-atherosclerotic PVD risk,
and while there have been numerous studies describing alterations to vascular reactivity, microvascular
network structure and microvessel wall mechanics in OZR, the ability to extend these observations to an
integrated system for the regulation of blood flow has been far more limited. While several studies have
indicated that functional dilation (Xiang et al. 2008; 2006) or hyperemia (Frisbee, 2004; 2003) are
impaired in skeletal muscle of OZR as compared to LZR, these remain superficially described, and results
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from recent study suggests that the integration across vascular structure/function relationships, the
regulation of perfusion, functional hyperemia and skeletal muscle fatigue resistance may be more
complicated than has previously been appreciated (Frisbee et al. 2009).
The initial observations from the first section of this study demonstrate that the increased
resistance across the skeletal muscle microcirculation of OZR is multi-factorial in nature. While the
a

1

2

adrenoreceptor

blockade (Figure 1), this is clearly a more complicated process, and one that appears to involve alterations
to endothelial function. While data in Figure 2 suggest that vascular responses to TxA2 are not altered in
OZR, supporting earlier observations (Goodwill et al. 2008), previous studies provided compelling
evidence that vascular production of TxA2, elevated in OZR (Xiang et al. 2008; 2006), can compromise
functional dilation and hyperemic responses within the distal microcirculation (where contribution to
overall resistance is lower; Greene et al.

1989) (Frisbee et al. 2009; Xiang et al. 2008; 2006).

Additionally, the muted response to the endothelium-dependent agonist methacholine in OZR was
partially ameliorated by pre-treatment with the antioxidant TEMPOL (and was consistently abolished by
the nitric oxide synthase inhibitor L-NAME), clearly indicating the impairments to nitric oxide
bioavailability through oxidant scavenging, an especially compelling issue for several reasons. Not only
does elevated systemic oxidant stress in OZR have the capacity to severely compromise nitric oxide
bioavailability, it also has the capacity to alter arachidonic acid metabolism leading toward the increased
generation of TxA2 (Goodwill et al. 2008; Zou, 2007; Zou et al. 2004). While these can obviously have
immediate impacts on vascular tone regulation themselves, alterations in NO and TxA2 bioavailability in
the microcirculation of OZR have also been demonstrated to contribute to significant changes to the
patterns and severity of adrenergic constriction (Stepp and Frisbee, 2002), myogenic activation (Frisbee et
al.2002), and the integration of these parameters for the determination of net vascular tone (Frisbee et al.
2009).
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The second portion of this study focused on relationships between vascular function, blood flow
and muscle fatigue resistance in OZR under control conditions and in response to the imposed
interventions of phentolamine, TEMPOL and SQ-29548. As compared to LZR, OZR exhibited a blunted
functional hyperemia and an elevated vascular resistance across gastrocnemius muscle across the
continuum of metabolic demand. Interestingly, this was also accompanied by a reduction in oxygen
extraction and a compromised VO2 in OZR, which, not surprisingly, was strongly predictive of an
impaired muscle performance. This is a particularly intriguing outcome for multiple reasons. The
gastrocnemius muscle was driven to contract via electrical stimulation of the sciatic nerve, and not only
were the stimulation parameters identical between strains, but gastrocnemius mass was also very similar,
which should have minimized differences between metabolic demand and muscle performance between
the two strains. Further, at this age, daily physical activity is very similar between LZR and OZR (Stepp
et al. 2004), fiber type profiles are similar (Adachi et al. 2007; Pujol et al. 1993), and the maximum
developed tension was nearly identical between the two strains (Table 1). As such, results from these
experiments strongly suggest that impairments to muscle performance in OZR at this age appear to reflect
an altered behavior within blood delivery/distribution in the microcirculation (i.e. O2 flux across the
working muscle), rather than overt dysfunction within skeletal muscle myocyte and motor unit
recruitment patterns. However, it must be emphasized that these conclusions are relevant for OZR at this
age only, as previous studies have clearly demonstrated significant, although variable, alterations to
contractile and metabolic functions of skeletal muscle myocytes in OZR afflicted with the metabolic
syndrome with increasing age (Campion et al. 1987; Farkas et al. 1994; He et al. 1995).
At the lower end of this continuum of metabolic demand, blood flow to gastrocnemius muscle of
OZR was restrained by increased adrenergic tone, as infusion of phentolamine abolished the elevated
vascular resistance (Figures 4 and 5). However, adrenergic constraint appeared to play little role in terms
of the poor oxygen extraction and VO2, as these were unaffected by phentolamine infusion. In contrast,
the endothelial dysfunction in OZR was not a significant contributor to perfusion resistance across the
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gastrocnemius muscle, as neither TEMPOL nor SQ-29548 altered femoral artery blood flow. What was
most compelling was that TEMPOL and SQ-29548 improved oxygen extraction across the gastrocnemius
of OZR as compared to LZR, although VO2 remained low owing to the lack of an impact on blood flow.
These relationships were also evident in the gastrocnemius of OZR working at 3 Hz contractions (Figure
6), wherein the influence of phentolamine, while decreased with elevated metabolic demand, was
primarily via reduced blood flow resistance while TEMPOL and SQ-29548 improved oxygen extraction,
and the combined influence of all three agents improving VO2 and muscle performance to the greatest
extent. The condition at 5 Hz (Figure 7) contractions was somewhat different owing to the structural
remodeling of the microvessel wall and networks to impose an upper ‘ceiling’ on bulk blood flow to the
muscle in OZR (Frisbee, 2005). As such, phentolamine was without effect on resistance in OZR,
although its restrictive effect was diminishing with increased contraction frequency owing to metabolic
sympatholysis (Frisbee, 2004). However, TEMPOL and SQ-29548 retained their ability to improve
oxygen extraction and conductance such that an optimal muscle VO2 under these conditions in OZR was
realized. Not surprisingly, regardless of metabolic demand, optimization of bulk blood flow, muscle
oxygen conductance in OZR, specifically following treatment with all three pharmacological agents, was
associated with the greatest improvement to gastrocnemius muscle fatigue resistance.
Taken together, the results of the present study have three significant and novel implications. The
first of these is the altering blood flow alone cannot restore skeletal muscle performance within the OZR
model of PVD. This observation is in some contrast to the accepted interpretations of PVD, wherein a
consistent assumption is that improving blood flow to active tissue, and certainly in proportion to the
continuum of metabolic demand (i.e. O2 uptake), would improve functional outcomes.

That an

intervention which enhanced functional hyperemia was ineffective at improving muscle oxygen
conductance and performance emphasizes the complexity of the processes affecting the diffusional
conductance of oxygen that is central to the poor outcomes identified in OZR and the strong relationship
determined between muscle O2 conductance and the fatigue response (Figure 8).
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Importantly, treatment of OZR with TEMPOL or SQ-29548 improved oxygen flux across the
microcirculation of the gastrocnemius muscle with minimal impact on aggregate vascular resistance. This
observation suggests that the beneficial impact of improving endothelial function with regard to
enhancing the integrated outcome of muscle performance may be the result of optimizing hemodynamic
behavior in the distal microcirculation (where localized mass transport and exchange phenomena are most
relevant) than in the proximal microcirculation (where the regulation of perfusion resistance is most
relevant). This observation is be supported by the muscle performance data in the present study, wherein
neither phentolamine nor TEMPOL/SQ-29548 alone improved muscle performance, while only combined
treatment with all three agents reduced fatigue development. This apparent spatial distinction of the
major contributors to poor perfusion and muscle performance outcomes, with the beneficial impacts of
adrenoreceptor blockade being primarily relevant in the proximal microcirculation and those for improved
endothelial dysfunction being primarily relevant in the distal microcirculation represents the second major
implication and novel observation of the results present study.
The concept involving the spatial relevance of interventions suggests the third major implication
of the present study. The results of the previous study indicated that one of the hallmark characteristics of
the distal microcirculation within in situ cremaster muscle of OZR was that perfusion distribution at
microvascular bifurcations was more heterogeneous than in LZR, with potential contributors to this
derangement being elevated oxidant stress and increased TxA2 production (Frisbee et al. 2009).
Speculatively, this may be the underlying physiological/hemodynamic mechanism for the impact of
TEMPOL/SQ-29548 on improving oxygen flux in contracting muscle of OZR in the present study. If
development of PVD in OZR is characterized by an increasing perfusion heterogeneity at microvascular
bifurcations, resulting in a poor pattern of oxygen extraction across the muscle through an increasing
propensity for ‘high flow pathways’ with lower extraction and ‘low flow pathways’ which become flowlimited, this could compromise net oxygen extraction and be reflective of a generalized impairment to
mass transport and exchange across the skeletal muscle microcirculation. Indeed, this process is akin to
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matching of ventilation and perfusion in the lung, which is known to be an important determinant in
transfer of O2 (i.e. O2 conductance) from alveolar gas into blood. Further interrogation of the contributing
physiological, biochemical and molecular signaling mechanisms, their spatio-temporal distribution, their
interactions, and the potential for ameliorative intervention appears to be well justified.
While the results of this study provide for a compelling framework for the interrogation of the
relationships between perfusion and fatigue in skeletal muscle under conditions of the metabolic
syndrome, one inherent limitation that should be acknowledged is the preparation itself. The combination
of a barbiturate anesthetic, which can inhibit reflex sympathetic excitation as a result of the muscle
contraction, clearly has the potential to impact the results of study in an unpredictable manner. Further,
the potential for electrical activation of sympathetic postganglionic fibers and group IV afferents as a
result of the current applied to the sciatic nerve cannot fully be discounted. Given these inherent
limitations to the preparation, further effort into the verification and potential application of a decerebrate
preparation without the necessity of anesthesia where the skeletal muscles in question can be activated via
direct stimulation of ventral roots may be warranted.
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Table 1. Baseline characteristics of 15-17 week-old LZR and OZR used in the present study. * p<0.05
versus LZR.

LZR

OZR

Mass (g)

3668

68411*

MAP (mmHg)

101±5

124±6*

[Glucose]plasma (mg/dl)

111±10

184±14*

[Insulin]plasma (ng/ml)

2.0±0.4

9.4±1.1*

[Cholesterol]plasma (mg/dl)

78±9

138±12*

[Triglycerides]plasma (mg/dl)

84±11

348±19*

[Nitrotyrosine]plasma (ng/ml)

14±4

48±8*

384±28

369±27

Maximum Tension Development (g/g)
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Table 2. Arterial and femoral venous blood oxygen content values (ml O2/dL blood) from LZR and OZR under the conditions of the present
study. Data are presented under resting conditions and across levels of increasing metabolic demand.

Rest
CaO2

1Hz
CvO2

CaO2

3Hz
CvO2

CaO2

5Hz
CvO2

CaO2

CvO2

LZR

20.8±1.1 14.2±1.1 20.7±1.1 12.1±0.8 20.7±1.1 11.0±1.2 20.6±1.1

7.4±0.9

OZR

21.0±0.9 15.9±1.0 20.6±1.0 13.9±1.4 20.6±1.1 13.2±1.6 20.8±1.1

9.9±1.4

OZR+Phentolamine 20.7±0.9 15.2±0.9 20.1±0.9 14.1±1.2 19.9±1.1 13.1±0.9 20.7±1.2 10.1±1.6
OZR+TEMPOL

20.7±1.0 14.3±1.0 20.6±1.0 11.8±1.5 20.8±1.0 10.8±1.3 20.2±1.2

6.9±1.5

OZR+SQ-29548

20.9±0.8 13.9±1.0 19.9±1.4 12.0±1.2 20.8±1.2 10.9±1.6 19.9±1.1

7.1±1.2

OZR+All

20.7±0.9 14.1±1.1 20.4±0.9 12.0±1.1 20.6±1.1

6.7±1.5

9.8±1.5

20.5±1.3
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FIGURE LEGENDS
Figure 1. Arterial pressor responses and gastrocnemius muscle perfusion in LZR and OZR following
intravenous infusion of the adrenoreceptor agonist phenylephrine (
in response to pre-

1

2

) under control conditions and

adrenoreceptor antagonist phentolamine (10 mg/kg). Data

(meanSE) are presented for changes in mean arterial pressure (Panel A), femoral artery blood flow
(Panel B) and vascular resistance across the gastrocnemius muscle (Panel C). * p<0.05 vs. LZR; † p<0.05
vs. OZR; n=6 animals under each condition.

Figure 2. Arterial pressor responses and gastrocnemius muscle perfusion in LZR and OZR following
intravenous infusion of the TxA2 mimetic U46619 (

) under control conditions and in response to

pre-treatment with the PGH2/TxA2 receptor antagonist SQ-29548 (10 mg/kg). Data (meanSE) are
presented for changes in mean arterial pressure (Panel A), femoral artery blood flow (Panel B) and
vascular resistance across the gastrocnemius muscle (Panel C). * p<0.05 vs. LZR; † p<0.05 vs. OZR; n=6
animals under each condition.

Figure 3. Arterial pressor responses and gastrocnemius muscle perfusion in LZR and OZR following
intravenous infusion of the endothelium-dependent dilator agonist methacholine (

) under control

conditions and in response to pre-treatment with the superoxide dismutase mimetic TEMPOL (50 mg/kg).
Data (meanSE) are presented for changes in mean arterial pressure (Panel A), femoral artery blood flow
(Panel B) and vascular resistance across the gastrocnemius muscle (Panel C). * p<0.05 vs. LZR; † p<0.05
vs. OZR; n=6 animals under each condition.
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Figure 4. Hemodynamic and oxygen uptake responses across gastrocnemius muscle of LZR and OZR
under resting conditions. Data (meanSE) are presented for femoral artery blood flow (Panel A),
vascular resistance across the gastrocnemius muscle (Panel B), oxygen extraction (Panel C) and oxygen
uptake (VO2) by the muscle (Panel D). Values are presented under control conditions and following
treatment of OZR with phentolamine (10 mg/kg), TEMPOL (50 mg/kg), SQ-29548 (10 mg/kg) or all three
substances. * p<0.05 vs. LZR (n=5 animals); † p<0.05 vs. OZR (n=15 for control; n=5 for each treatment
group; all oxygen extraction and VO2 data are from n=5 animals). The legend for all panels is presented
in Panel A.

Figure 5. Hemodynamic and oxygen uptake responses across gastrocnemius muscle of LZR and OZR in
response to three minutes of 1 Hz muscle contraction. Data (meanSE) are presented for femoral artery
blood flow (Panel A), vascular resistance across the gastrocnemius muscle (Panel B), oxygen extraction
(Panel C), oxygen uptake (VO2) by the muscle (Panel D) and developed tension by the gastrocnemius
(Panel E).

Values are presented under control conditions and following treatment of OZR with

phentolamine (10 mg/kg), TEMPOL (50 mg/kg), SQ-29548 (10 mg/kg) or all three substances. * p<0.05
vs. LZR (n=5 animals); † p<0.05 vs. OZR (n=15 for control; n=5 for each treatment group; all oxygen
extraction and VO2 data are from n=5 animals). The legend for all panels is presented in Panel A.

Figure 6. Hemodynamic and oxygen uptake responses across gastrocnemius muscle of LZR and OZR in
response to three minutes of 3 Hz muscle contraction. Data (meanSE) are presented for femoral artery
blood flow (Panel A), vascular resistance across the gastrocnemius muscle (Panel B), oxygen extraction
(Panel C), oxygen uptake (VO2) by the muscle (Panel D) and developed tension by the gastrocnemius
(Panel E).

Values are presented under control conditions and following treatment of OZR with

phentolamine (10 mg/kg), TEMPOL (50 mg/kg), SQ-29548 (10 mg/kg) or all three substances. * p<0.05
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vs. LZR (n=5 animals); † p<0.05 vs. OZR (n=15 for control; n=5 for each treatment group; all oxygen
extraction and VO2 data are from n=5 animals). The legend for all panels is presented in Panel A.

Figure 7. Hemodynamic and oxygen uptake responses across gastrocnemius muscle of LZR and OZR in
response to three minutes of 5 Hz muscle contraction. Data (meanSE) are presented for femoral artery
blood flow (Panel A), vascular resistance across the gastrocnemius muscle (Panel B), oxygen extraction
(Panel C), oxygen uptake (VO2) by the muscle (Panel D), normalized O2 conductance across the muscle
(Panel E) and developed tension by the gastrocnemius (Panel F). Values are presented under control
conditions and following treatment of OZR with phentolamine (10 mg/kg), TEMPOL (50 mg/kg), SQ29548 (10 mg/kg) or all three substances. * p<0.05 vs. LZR (n=5 animals); † p<0.05 vs. OZR (n=15 for
control; n=5 for each treatment group; all oxygen extraction and VO2 data are from n=5 animals). The
legend for all panels is presented in Panel B.

Figure 8. Correlation between O2 conductance (DmO2) and muscle performance in LZR (n=5) and OZR
(n=5-6) in response to three minutes of muscle contraction at a frequency of 5Hz. Values are presented
under control conditions and following treatment of OZR with phentolamine (10 mg/kg), TEMPOL (50
mg/kg), SQ-29548 (10 mg/kg) or all three substances. Data are presented for individual animals and the
equation for the line of best fit is determined using a least squares analysis.
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Conceptual Framework
The second chapter is entitled “Divergence Between Arterial Perfusion and Fatigue Resistance in
Skeletal Muscle in the Metabolic Syndrome”. This chapter takes the vascular impairments that render the
OZR unable to adequately match perfusion and demand, and give it functional relevance. It utilized the in
situ blood perfused gastrocnemius preparation and revealed that the increase in the OZR microvasculature
resistance is multifactorial in nature. There exists an impairment to bulk blood flow and also an inability
to extract oxygen in the OZR compared to the LZR. These impairments exist at rest as well as at low,
moderate, and high levels of electrical stimulus. The intervention that proved effective at restoring bulk
blood flow was phentolamine, an alpha-adrenoreceptor antagonist. The antioxidant TEMPOL or TxA2
receptor antagonist SQ-29548 proved effective at restoring oxygen uptake. However, none of the three
interventions alone were effective at restoring tension development in the OZR. It was only when the
combination of interventions was utilized that a significant improvement in performance was observed.
The importance of these findings is two-fold. The first is that alteration to structure-function relationships
via alpha-adrenergic and endothelial dysfunction has the ability to compromise functional hyperemia in
the OZR. The second is the observation that oxygen extraction and uptake is compromised in the OZR. At
this age (17 weeks) the OZR has the same activity and similar maximal developed tension and fiber types
compared to the LZR control. Thus one would expect a significantly higher oxygen extraction with the
estimated 25% rarefaction and lower blood flow accompanying this age group. This suggests that the
impairments to OZR skeletal muscle performance are being significantly influenced by alterations to
erythrocyte perfusion distribution.
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Chapter 3

SPATIAL HETEROGENEITY IN SKELETAL MUSCLE MICROVASCULAR BLOOD FLOW
DISTRIBUTION IS INCREASED IN THE METABOLIC SYNDROME
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ABSTRACT
Previous studies have demonstrated that the metabolic syndrome is associated with impaired skeletal
muscle arteriolar function, although integrating observations into a conceptual framework for impaired
perfusion in peripheral vascular disease (PVD) has been limited. This study builds on previous work to
evaluate in situ arteriolar hemodynamics in cremaster muscle of obese Zucker rats (OZR) to integrate
existing knowledge into a greater understanding of impaired skeletal muscle perfusion. In OZR cremaster

than in controls. However, while consistent, the underlying mechanistic contributors were spatially
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divergent a
microvascular bifurcations, with a steady decay with distance, while endothelial dysfunction was a
stronger contributor in distal bifurcations with no discernible role proximally. Using measured values of

distribution in distal arterioles than in controls; an effect that could only be rectified by combined
adrenoreceptor blockade and improvements to endothelial dysfunction. Intravascular
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I-albumin tracer

washout from in situ gastrocnemius muscle of OZR provided independent support for these observations,
indicating increased perfusion heterogeneity that was corrected only by combined adrenoreceptor
blockade and improved endothelial function. These results suggest that a defining element of PVD in the

heterogeneous and spatially distinct, and that interventions to rectify this negative outcome must take a
new conceptual framework into account.

Key Words: rodent models of obesity; microcirculation; skeletal muscle blood flow regulation; models of
peripheral vascular disease; blood flow heterogeneity; vascular dysfunction
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INTRODUCTION
For myriad social, biological and behavioral reasons (14, 26), Western societies and economies
are experiencing a robust growth in both the incidence and prevalence of obesity, impaired glycemic
control (both from insulin resistance and the more severe type II diabetes mellitus). While there are
multiple venues through which these conditions can impact public health, patient quality of life and
mortality (13, 26), one of the most common is via an elevated risk for the development of peripheral
vascular disease (PVD), which can generally be considered as an evolving condition wherein the ability
of the vasculature to effectively deliver and distribute blood perfusion relative to local metabolic demand
becomes increasingly compromised. While the presence of PVD based on structural alterations to larger
conduit arteries, including atherosclerotic plaques/lesions and other structural abnormalities that intrude
on the vascular lumen represents a major contributor to the overall prevalence of PVD (1, 9), the presence
of an array of ‘microvasculopathies’ that are not a function of structural hindrances to perfusion can also
represent a powerful contributor to a growing PVD under ‘non-atherosclerotic’ conditions (17, 34).
In the obese Zucker rat, classically considered as a model of the metabolic syndrome based on
chronic hyperphagia subsequent to a disruption of leptin signaling at its receptor, we (16, 19) and others
(40, 41) have demonstrated that basal perfusion and/or functional hyperemia can be compromised through
adrenergic-based elevations in vascular resistance (19, 35) or increased adrenergic signaling (31),
alterations to vascular endothelial function that can impact myogenic activation (21) and multiple
parameters of dilator responses (7, 8, 16, 23, 25, 37). However, an understanding of how this array of
contributors to an integrated vascular/perfusion-based outcome relevant for skeletal muscle performance
or fatigue resistance has proven to be an exceptionally difficult process owing to difficulties in translating
results in isolated tissues/ex vivo preparations to the functioning intact system, the inherent complexity of
studying multiple processes simultaneously and the challenges of accurately integrating the concepts of
space (location) and time into system behaviors and outcomes.

84

In our recent studies, we have provided evidence that the ability of in situ skeletal muscle of OZR
to resist fatigue under conditions of elevated metabolic demand is partially a function of the inability to
reduce the aggregate vascular resistance through the microvascular network (which was largely dependent
on reducing adrenergic constrictor tone) and elevate oxygen extraction and conductance within the distal
microcirculation (which was predominantly related to elevated vascular oxidant stress and the effects of
the increased vascular production of thromboxane A2; TxA2) (15, 16). While alterations to skeletal
muscle performance with either adrenoreceptor blockade or antioxidant treatment/PGH2/TxA2 receptor
antagonism were trivial, the combination of these interventions effectively resulted in a maximal
improvement to perfusion, O2 extraction, O2 conductance (a lumped parameter describing skeletal muscle
oxygen flux that reflects all of the resistances for O2 in moving from red cell to muscle fiber
mitochondria; Ref. 38), resulting in significant improvements to muscle oxygen uptake (VO 2) and
contractile performance. These observations, which help to identify the specific role of microvascular
dysfunction in limiting VO2 and muscle performance at low, moderate and near maximal metabolic
demand, are especially intriguing given the results from previous studies which suggested that one of the
defining characteristics of PVD and a poor perfusion outcome in OZR is an increasingly heterogeneous
blood flow distribution at microvascular bifurcations within skeletal muscle (16). While that study
provided an initial insight revealing the presence of increased perfusion heterogeneity at bifurcations,
those results focused on only the distal microcirculation and provided no insight into either the presence
of perfusion heterogeneity at different levels of the microcirculation or how contributing elements to this
effect might vary with longitudinal position within the networks (16). In addition, those previous data
provided no information regarding the functional outcomes or implications that result from the increased
perfusion heterogeneity.
The primary purpose of the present study was to interrogate the presence of the increased
perfusion heterogeneity at four distinct levels of the skeletal muscle microcirculation of OZR, to
determine the physiological mechanistic contributors to this process (and if they vary with position within
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the microcirculation), and to predict the functional implications of this process for perfusion patterns
within the distal levels of the microcirculation. A secondary purpose of the present study was to utilize
indicator dilution analyses in intact skeletal muscle to determine the presence and impact of increased
microvascular perfusion heterogeneity in skeletal muscle of OZR and the role of the physiological
mechanisms determined at the higher level of resolution (individual bifurcations) in contributing to these
outcomes. Specifically, these studies tested the hypothesis that the presence of increased heterogeneity of
perfusion distribution at successive bifurcations within the skeletal muscle microcirculation results in
severe impairments to distal arteriolar blood flow distribution, and is a major contributor to the impaired
muscle performance outcomes that have been previously demonstrated in OZR (15, 20).
MATERIALS AND METHODS
Animals: Male lean (total n=26) and obese Zucker rats (total n=102), purchased from Harlan, were fed
standard chow and drinking water ad libitum and were housed in the animal care facility at the West Virginia
University Health Sciences Center or the Medical College of Wisconsin. All protocols received prior IACUC
approval. At ~17 weeks of age, rats were anesthetized with injections of sodium pentobarbital (50 mg/kg,
i.p.), and received tracheal intubation to facilitate maintenance of a patent airway. In all rats, a carotid artery
and an external jugular vein were cannulated for determination of arterial pressure and for infusion of
supplemental anesthetic and pharmacological agents, as necessary. Any animal in which mean arterial
pressure was found to be below 85 mmHg, or where MAP had decreased by more than 15% from that
following equilibration (without any pharmacological intervention) was not used in the present study. Blood
samples were drawn from the venous cannula for determination of glucose and insulin concentrations
(Millipore, Billerica, MA) as well as cholesterol/triglyceride levels (Wako Diagnostics, Richmond, VA), and
nitrotyrosine (Oxis International. Foster City, CA). Unless otherwise noted, all drugs and chemicals were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
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Preparation of In Situ Cremaster Muscle: In each rat (LZR n=16; OZR n=74), an in situ cremaster
muscle was prepared for study using intravital microscopy as described previously (16).

After

completion of the in situ cremaster muscle preparation, the tissue was continuously superfused with
physiological salt solution (PSS) equilibrated with a 5% CO2-95% N2 gas mixture, and maintained at
35C as it flowed over the muscle. Volume flow rate was ~3.0 ml/min. The ionic composition of the
PSS was as follows (mM): NaCl 119.0, KCl 4.7, CaCl2 1.6, NaH2PO4 1.18, MgSO4 1.17, NaHCO3 24.0,
and disodium EDTA 0.03. Arteriolar diameters were measured with a video-micrometer. Following a 30
minute period of equilibration following the surgical preparation, arterioles and bifurcations within five
distinct di

-

-3A), 3) ~60
-

-5A).

Arterioles/bifurcations were selected based on the following criteria: 1) distance from any site of incision,
2) presence of significant vascular tone (assessed by brisk dilator response to challenge with 10 -3 M
adenosine), 3) clearly discernible walls, 4) a rapid and stable level of erythrocyte perfusion, and 5) the
presence of two clearly defined ‘daughter’ branches that also met criteria 1-4. Please see Figure 1 for a
schematic representation of these concepts.
The mechanical (using on-screen videomicroscopy) and perfusion (using optical Doppler
velocimetry) responses of both the ‘parent’ and ‘daughter’ arterioles within a bifurcation class were
assessed under resting conditions within the cremaster muscle of each rat. All procedures were performed
under control conditions in LZR and OZR, and following treatment of the in situ cremaster muscle with
the anti-oxidant TEMPOL (10-3 M), the TxA2 receptor antagonist SQ-29548 (10-4 M), the nitric oxide
synthase inhibitor L-NAME (10-4

1

2

adrenergic receptor antagonist phentolamine (10-5

M); within the superfusate solution. All treatments to the cremaster were of a minimum of 40 minutes
duration prior to any subsequent experimental manipulation.
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Interrogation of Arteriolar Bifurcations: Within each animal, the numbers of bifurcations of each order
that were studied differed depending on longitudinal position in the arteriolar network. Bifurcations
spanning 1A-2A arterioles averaged 1-2/animal, while bifurcations spanning 3A-4A and 4A-5A arterioles
averaged between 3-4/animal.

For an individual measurement, arteriolar diameter and erythrocyte

velocity were sampled for 10 seconds. All arterioles and bifurcations were selected on the basis of the
criteria outlined above and were placed into their categories by size rather than by strict branch number.
This was done as our experience demonstrated that branch order classification limited data collection as
frequently not all inclusion criteria could be satisfied.
No cremaster muscle was exposed to all interventions as this would have compromised data
quality owing to experiments of excessive duration. In addition to the collection of responses under
control conditions, individual cremaster preparations were exposed to a maximum of three interventions,
each separated by ~30 minutes of washout.

Treatment or washout effectiveness was verified by

determining abolition or recovery of mechanical responses following challenge with appropriate agonists
1

adrenergic antagonist phenylephrine, the stable TxA2 mimetic U-46619, and the endothelium

dependent dilator agonist acetylcholine).

Maximum experimental duration from preparation to

termination was approximately five hours, after which time all animals were humanely euthanized by an
intravenous overdose of anesthetic followed by a bilateral pneumothoracotomy.

the proportion in the daughter arteriole with the higher perfusion.

Within an individual arteriolar

bifurcation, the maximum disparity between parent arteriole blood flow and the summated daughter
arteriolar perfusion did not exceed 15%. If this error was consistent in terms of magnitude and direction,
this could lead to a biased outcome on the distal arteriolar perfusion distributions. However, there is no a
priori reason to believe that this would be a consistent error in terms of artificially increasing or
decreasing Q determination, and it is more likely that measurement errors would be randomly distributed.
To the extent possible, all measurements within an experiment were taken at the same arteriolar
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bifurcation sites within a specific animal. However, this was not possible in every animal, owing to
alterations to visibility that can develop with time and interventions in this experimental preparation.
Preparation of In Situ Blood Perfused Hindlimb: In a separate set of age-matched LZR (n=10) and OZR
(n=28), the left hindlimb of each animal was isolated in situ (20) with minor modifications. Heparin (500
IU/kg) was infused via the jugular vein to prevent blood coagulation. Subsequently, an angiocatheter was
inserted into the femoral artery, proximal to the origin of the gastrocnemius muscle to allow for bolus tracer
injection. Additionally, a small shunt was placed in the femoral vein draining the gastrocnemius muscle that
allowed for diversion of flow into a port which facilitated sampling of the venous effluent. Finally, a
microcirculation flow probe (Transonic; 0.5/0.7 PS) was placed on the femoral artery to monitor muscle
perfusion.

In indi

1

2

adrenoreceptor

antagonist phentolamine (10 mg/kg), TEMPOL (50 mg/kg) and/or SQ-29548 (10 mg/kg). Effectiveness of
these interventions was assessed by monitoring the changes in arterial pressure in response to intravenous
16).
Upon completion of the surgical preparation, the gastrocnemius muscle was allowed 30 minutes of
self-perfused re
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I-

-Elmer, Shelton, CT) was injected as a

spike bolus (injection time <0.5 s) into the arterial angiocatheter and venous effluent samples were collected
at a rate of 1/s for the subsequent 35 seconds. Venous effluent samples were then immediately transferred
into silicate tubes and placed into a gamma counter for activity determination. Each rat received an
intravenous infusion of homologous donor erythrocytes suspended in PSS at the individual animal’s
hematocrit (~45%) to replace the lost volume, and this was allowed a minimum of 20 minutes for circulation
prior to subsequent intervention. In order to assess the potential for leakage of the labeled albumin from
the intravascular space as a source for error, the gastrocnemius muscle was cleared by perfusion with
physiological salt solution following euthanasia. Subsequent to a determination of mass, the muscle was
placed in the counter for determination of residual activity. Residual activity within the gastrocnemius
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muscle did not exceed 200 cpm/animal; a level that was far lower than those determined in the venous
blood aliquots. All protocols had received prior approval from the Radiation Safety Office at the WVU
Health Science Center.
Data and Statistical Analyses: Arteriolar perfusion in both parent and daughter vessels within in situ
cremaster muscle of LZR and OZR was calculated as:
(

)(

)(

)

Equation 1

where, Q represents arteriolar perfusion (nl•s-1), V represents the measured red cell velocity from the
optical Doppler velocimeter (mm•s-1; with V/1.6 representing an estimated average velocity; Ref. 11), and
perfusion in the daughters was determined as
the sum of the individual perfusion rates, and the proportion of flow within each was determined as the

in the daughter vessel to the total flow in the parent vessel. As an example, if flow distribution was

proportion of flow in one daughter arteriole was 60%, for that bifurcation would be 0.6, with flow distribution
being 0.6 in the ‘high perfusion’ arteriole and 0.4 in the ‘low perfusion’ arteriole (5). Please see Figure 1 for
additional clarification.
erfusion distribution

cremaster muscle were inserted into a simulation of a dichotomous branching network with each outflow
(daughter) arteriole arising

-

perfusion. These respective values of daughter arteriolar perfusion then become in the inflow perfusion
(parent) values for the next generation bifurcation.

The process was repeated over a total of eight

bifurcations, resulting in 28
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the 1A-2A, the 2A-

-

generations, and three 4AFor the
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I-albumin washout, four standard parameters describing characteristics of tracer

washout curves, including mean transit time ( t ), relative dispersion (RD), skewness ( 1 ), and kurtosis
(  2 ), were computed as functions of the transport function h(t) (6). The tail of tracer washout curves are
extrapolated in the form of single exponential time course to allow for computing the four parameters by
the integration for sufficiently long time for Equation 3 to converge (24). In this study, experimentallymeasured time courses are extrapolated to 100 seconds, at which C(t) is estimated to be less than 10-9 of
the maximum washout tracer activity. The transport function h(t) is estimated from

h(t )  C(t )





0

C(t )dt

Equation 2

where C(t) is the time course of activity of intravascular tracer in outlet flow exiting the collecting tube.
The mean transit time t is calculated from experimentally measured washout curves according to:


t   t  h(t )dt

Equation 3

0

The RD of h(t) is a measure of the relative temporal spread of h(t) and computed as the ratio of standard
deviation of h(t) to the mean transit time from:
1/ 2

2
 

RD     t  t   h(t )dt 
 0


/t

Equation 4

The skewness ( 1 ) is a measure of asymmetry of h(t) and computed from:


1    t  t 
0

3

2
 

 h(t )dt    t  t   h(t )dt 
0



3/ 2

Equation 5

Skewness is a measure of the asymmetry of the perfusion distribution. In other words, it is a measure of
the extent to which the perfusion distribution is skewed (as opposed to simply being shifted) to higher or
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lower values of perfusion. The kurtosis (  2 ) is a measure of deviation of h(t) from a normal distribution
and computed from:


2    t  t 
0

4

2
 

 h(t )dt    t  t   h(t )dt 
 0


4/2

3 .

Equation 6

Kurtosis is a measure of the “sharpness of the peak” of the perfusion distribution. The familiar Gaussian
bell-

2

2

indicate a sharper peak than a Gaussian. The four

parameters are estimated based on the above equations for each animal in each experimental group.
All data throughout the manuscript are presented as mean±SE. Statistically significant differences in
measured and calculated parameters were determined using a one sample t-test (differences from zero),
Student’s t-test or analysis of variance (ANOVA) with Student-Newman-Keuls post-hoc test used as needed.
Analyses of the simulation results for distal arteriolar perfusion distribution (Figure 6) utilized descriptive
statistics (variance, skewness, kurtosis, range, maximum, minimum, quartiles (25%, 50% and 75%) and the
75-25% interquartile difference). Statistically significant differences between the frequency distributions for
the simulations were evaluated using the Kruskal-Wallis test, although because indices of central tendency
were not different between groups (due to the normalization procedures), multiple post-hoc comparisons
were not possible. In all cases, p<0.05 was taken to reflect statistical significance.
RESULTS
Baseline characteristics describing the animals used in the present study are summarized in Table
1. At ~17 weeks of age, male OZR were significantly heavier than LZR and, in addition to a moderate
hypertension, hypercholesterolemia and hyperglycemia, also exhibited a severe elevation in plasma levels
of insulin, triglycerides and nitrotyrosine. Data describing the perfusion characteristics of the individual
cremasteric arteriolar segments (described above) under the experimental conditions of the present study
are summarized in Table 2. These data clearly demonstrate general differences between arteriolar
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diameter and perfusion characteristics that are distributed longitudinally throughout the cremasteric
microcirculation under the conditions of the present study.
Figure 2 presents the magnitude of the perfusion distribution coefficie

control conditions and in response to the interventions employed in the present study (Panel A) and the
extent to which specific interventi
Specifically, the ordinate in Figure 2B is defined as:

 





Recovery(%)  1  OZR * LZR  100%   OZR OZR*  100%
 OZR   LZR 

  OZR   LZR 
where  OZR * represents one of the treatments indicated.

Equation 7

Full (100%) recovery indicates that the

In these proximal resistance arterioles,  was significantly elevated in OZR as compared to LZR,
although this was restored by treatment of the cremaster muscle with the adrenoreceptor antagonist
phentolamine (either alone or in combination with any other agent).

In contrast, treatment with

TEMPOL, SQ-29548, or L-NAME, either alone or in any combination was without effect in terms of
restoring the normal magnitude of  unless phentolamine was also present.
The magnitude of  (Panel A), and its recovery following intervention (Panel B), in arteriolar
bifurcations spanning 2A (80 m) parent to 3A (60 m) daughter arterioles in cremaster muscle of LZR
and OZR are summarized in Figure 3. In contrast to the data presented in Figure 2, the ability of
phentolamine to restore normal levels of  in OZR at this level of the cremasteric microcirculation, while
still statistically significant, was blunted as compared to responses at the more proximal bifurcation.
Neither TEMPOL nor SQ-
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microcirculation when applied individually.

Further, when either TEMPOL or SQ-29548 was co-

administered with phentolamine, these restorative effects appeared to be partially additive, as the
mpacted by
amelioration of vascular oxidant stress by co-administration with TEMPOL.

s in cremaster muscle of LZR
and OZR are presented in Figures 4 and 5 respectively.

At these levels of the cremasteric

OZR to the levels determined in LZR. However, improvements to endothelial function from TEMPOL
and SQmicrocirculation at these positions within the networks. As with the data presented above, we were
unable to determine an apparent role for nitric oxide bioavailability in terms of regulating  in the
cremasteric microcirculation of OZR.
Using the data presented above for  distribution at the different levels of the cremasteric
microcirculation of LZR and OZR under the employed experimental interventions, Figure 6 presents the
predicted outcomes on perfusion distribution within the terminal arterioles, and Table 3 summarizes the
results of the statistical analyses of the distribution outcomes presented in Figure 6. These predictions are
based on a dichotomous branching network of eight bifurcations between the major perfusing arteriole
and the terminal arterioles, resulting in a total of 256 terminal arterioles. These data clearly predict that
the shifts in  identified through direct examination of the cremaster muscle result in profound alterations
in the outcomes for distal arteriolar perfusion distribution. While the distribution for volume flow in any
single arteriole, relative to the mean flow across all 256 arterioles, was relatively tight in LZR as
compared to OZR (Figure 6, Panel A versus Panel B), demonstrating much lower degrees of variability,
skewness and kurtosis, with a much lower inter-quartile difference (Table 3), treatment with the
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individual interventions of phentolamine, TEMPOL and SQ-29548 (Figure 6, Panels C-E, respectively)
all results in moderate improvements to the variability, skewness, kurtosis and interquartile difference of
the distributions (Table 3). However, the greatest magnitude of improvement was identified under
conditions of adrenoreceptor blockade combined with either TEMPOL or SQ-29548 (or both). These
perfusion outcome predictions and statistical analyses also suggest that vascular nitric oxide
bioavailability, either under control conditions in OZR skeletal muscle at rest or following reductions to
vascular oxidant stress that have been repeatedly demonstrated to increase NO bioavailability, may not

Figure 7 presents the mean tracer washout curves for
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I-albumin from the isolated

gastrocnemius muscle of LZR and OZR following the pharmacological treatments described above.
Figure 8 summarizes data describing the aggregate washout curves. Mean transit time of the tracer across
the gastrocnemius was very similar across all groups, suggesting that the relationship between bulk blood
flow to the gastrocnemius muscle and vascular volume under the experimental conditions of the present
study were very similar across groups (Panel A). The relative dispersion of tracer across the muscle (RD;
Panel B) was significantly elevated in OZR as compared to LZR under control conditions, indicative of
an increased perfusion heterogeneity throughout the microcirculation of the gastrocnemius muscle.
Treatment of OZR with phentolamine (with or without TEMPOL or SQ-29548) significantly improved
RD, although treatment with TEMPOL and/or SQ-29548 in the absence of the adrenoreceptor blockade
was generally less effective. Both the skewness (Panel C) and the kurtosis (Panel D) of the tracer
washout curves were reduced in OZR as compared to LZR, and these shifts in the washout patterns were
improved toward the level in LZR as a result of the experimental interventions, with the greatest impact
being determined in response to combined treatment with phentolamine and TEMPOL/SQ-29548. Based
on the data presented in Figures 2-6, this final group of experiments and analyses did not involve direct
manipulations to vascular nitric oxide bioavailability.
DISCUSSION
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A recent study has demonstrated that the increased rate of skeletal muscle fatigue in OZR,
defined as the percent decline in developed tension over the duration of the imposed bout of contraction,
is not necessarily improved subsequent to an improved functional hyperemic response (15). However,
one of the central observations of that study was that the vascular dysfunction in the skeletal muscle
microcirculation of OZR impacted muscle performance outcomes through two distinct patterns, such that
impairments within the proximal microcirculation restricted volume perfusion and responses in the distal
microcirculation impaired normal patterns of perfusion:demand matching.

Further, that study also

implicated the possibility that the physiological and cellular mechanisms underlying the vascular
dysfunction within the skeletal muscle microcirculation may be spatially distinct, with alterations to
adrenergic constraint on perfusion dominating with regard to the regulation of bulk perfusion, and the
endothelial dysfunction playing a stronger role in terms of the higher resolution matching of blood flow
distribution to metabolic demand (15). When taken into account with our previous studies demonstrating
the potential for increased perfusion heterogeneity at microvascular bifurcations as a defining
characteristic of the metabolic syndrome in skeletal muscle of OZR (16), a greater understanding of the
impact of the metabolic syndrome on integrated microvascular function represented a critical need. As
such, the present studies were designed to determine whether the initial observation of perfusion
heterogeneity at arteriolar bifurcations is present throughout microvascular networks, what the
contributing mechanisms to this effect are, if they are spatially distinct, and what the functional outcomes
of the successive perfusion distribution events would be for blood flow at the level of the terminal
arterioles.
The foremost observation from the present study was that the increased heterogeneity at
microvascular bifurcations within skeletal muscle () of OZR was identified over four distinct bifurcation
classes spanning five arteriolar diameter ranges. While at bifurcations in LZR tended to be slightly
lower than 0.54 across all levels of arteriolar/bifurcation ranges, this value was elevated toward 0.60 in
OZR. The axis limits on the ordinates in Figures 2-
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While on the absolute scale the observed differences in  are relatively small, these differences are
significant statistically and their cumulative effects translate into physiologically significant differences in
function.

The consistency of the elevated within the microcirculation of OZR afflicted with the

metabolic syndrome suggests that this increased heterogeneity of perfusion at bifurcations may represent
a defining characteristic of PVD in this animal model. This observation suggests that, as blood flow
enters into the microvascular networks of the skeletal muscle of OZR, there is an increased heterogeneity
of distribution at bifurcations involving the larger resistance arterioles, where the result is the generation
of ‘high flow’ and ‘low flow’ daughter arterioles arising at this bifurcation. Essentially, this represents a
source for increased variability as compared to perfusion distribution in LZR, and through a repetitive
iteration at successive bifurcations will result in a striking increase to the heterogeneity of arteriolar
perfusion within the distal microcirculation; predicted in Figure 6.
Our recent study that initially identified the presence of an altered  in the skeletal muscle
microcirculation of OZR suggested that this effect was a function of combined alterations to adrenergic
tone and the evolving endothelial dysfunction in the metabolic syndrome, as acute interventions against
these negative outcomes changed  to levels that were similar to those determined in LZR (16). While the

microvascular network within OZR skeletal muscle, data from these experiments also demonstrated a
significant heterogeneity in terms of the physiological/cellular mechanisms which contribute to the

arterioles, the alteration
microvessel, as treatment with the adrenoreceptor antagonist almost completely removed the change in
in the present results was that
acute interventions designed to ameliorate microvascular dysfunction, the antioxidant TEMPOL and the
PGH2/TxA2 receptor antagonist SQarteriolar bifurcatio
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adrenoreceptor blockade was also evident. This relationship gradually changed with longitudinal position
in the microvascular networks, such that in smaller diameter bifurcations (2A-3A and 3A-4A), the impact

TEMPOL and SQto the most distal levels of the microcirculation (4A-5A), where adrenoreceptor blockade was entirely

support our previous initial observations, combined treatment with an adrenoreceptor antagonist and
either an antioxidant or the PGH2/TxA2
throughout the microvascular network. With the incorporation of the results from the present study, the
amelioration of different contributing mechanisms of dysfunction, while varying in proportion across
levels of the microcirculation, suggests that a multi-faceted approach against the microvasculopathy in
OZR is required to significantly improve integrated perfusion outcomes.
One of the more intriguing results of the present study is the lack of demonstrated evidence for a

treatment of OZR with L-

networks in that strain was

not surprising, as multiple previous studies have demonstrated that vascular NO bioavailability is
dramatically reduced in OZR at this age and treatment and that further antagonism of nitric oxide
synthase (NOS) is without effect (18). However, as previous studies have demonstrated that antioxidant

treatment with TEMPOL and L-

elling

in OZR. The current study employed pharmacological interventions targeted at determining the role of
NO bioavailability (L-NAME and TEMPOL) treatments. As such, this study does not rule out the
possibility that NO in other ‘stored’ forms, such as nitrosothiols could contribute, as any roles for these
sources for NO were not directly interrogated.
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While there is considerable ongoing effort to identify the molecular signaling cascades that
underlying specific identified sites of vascular dysfunction in the metabolic syndrome (2, 29, 30, 32),
these efforts can suffer from a lack of contextual relevance as it becomes exceptionally difficult to
integrate these myriad observations from highly reduced preparations into either a functioning tissue type
(e.g., vascular smooth muscle cell, isolated microvessel) or into an integrated system (e.g., blood perfused
skeletal muscle). The present study incorp
tissue perfusion distribution at in the distal microcirculation. Using a dichotomous branching network of
re able to predict
the perfusion distribution in a network consisting of 256 terminal arterioles (5A).

In these initial

simulations, the resulting frequency distributions reveal that distal arteriolar perfusion in OZR was
substantially more heterogeneous than in LZR, with a distribution characterized by an increased interquartile difference that reflects the genesis of a large number of ischemic pathways and a small number of
very high flow pathways that may represent functional thoroughfares.

While adrenoreceptor blockade

and improving endothelial dysfunction with TEMPOL or SQ-29548 each resulted in some improvement
to the perfusion distribution characteristics in the distal microcirculation, only combined interventions
with both phentolamine and TEMPOL/SQ-29548 allowed for a maximal improvement (i.e., recovery) in
the frequency distribution and its descriptive characteristics (Table 3) toward levels predicted in LZR.
Obviously, distal arteriolar perfusion distribution within the skeletal muscle will be neither discrete nor
clustered, and this is an artifact of the simulation employed. However, our simulation does illustrate both
a real broadening of the distribution with the presence of PVD in OZR, and the capacity for ameliorating
these negative outcomes with appropriately targeted interventions.

microvascular bifurcations in resting muscle, they may provide a partial explanation for the results from
our recent study that evaluated the fatigue resistance of in situ skeletal muscle of OZR across levels of
elevated metabolic demand (15). In that study, while the gastrocnemius muscle fatigue rate was elevated
in OZR as compared to that in LZR, single pharmacological interventions were of extremely limited
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effectiveness in improving the ultimate functional outcome of increased muscle performance. While
adrenoreceptor blockade with phentolamine improved bulk perfusion and active hyperemia,
improvements to muscle oxygen extraction, uptake (VO2) and oxygen conductance (DmO2) were
minimal.

Further, improving endothelial function with TEMPOL or SQ-29548 tended to improve

extraction, VO2 and DmO2, although minimal impacts on bulk perfusion and muscle performance were
identified. A significant improvement in muscle fatigue resistance was identified only when combined
interventions with phentolamine and TEMPOL/SQ-29548 were applied, and this was also associated with
the improvements to bulk perfusion, O2 extraction, VO2 and DmO2 (15, please see ref. 37 for full review).
When combined with the results of the present study, these data strongly suggest that the multi-faceted
approach to reducing proximal resistance to bulk perfusion in combination with improving distal
microvascular perfusion:demand matching represent a requisite condition to lessen the impact of PVD on
muscle performance outcomes.
One of the main considerations that must be addressed in the present study is that of the level of
resolution for the data.

The in situ cremaster muscle preparation allows for very high resolution

measurements of multiple arterioles throughout the tissue for both their mechanical (dimension) and
hemodynamic (RBC flux, volume blood flow) status. However, this preparation does not lend itself well
to the integrated study of the entire network at one time. We have employed the in situ gastrocnemius
muscle preparation for the integrated assessment of network function using tracer washout kinetics, as the
anatomy and the range of blood flow volumes to the muscle allow for an effective tracer washout protocol

physiological mechanistic contributors and its distribution with the results in the in situ gastrocnemius
muscle in our previous study is compelling, the intravascular washout experiments summarized in Figures
8 and 9 provide independent data that reflect the flow distributions throughout the gastrocnemius muscle
circulation. Since the washout of
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I-albumin (which is confined to the intravascular space) introduced

into the femoral artery immediately proximal to the gastrocnemius muscle reflects the whole-network
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flow distribution, any potential for a selection bias is eliminated. As presented in Figures 7 and 8, striking
differences in the washout kinetics were determined between LZR and OZR under the conditions of the
present study. In general, OZR manifested an earlier appearance time of tracer than in LZR as well as a
longer retention in the microcirculation. Speculatively, this change could reflect the combined influence
of both the ‘high flow’ and ‘low flow’ pathways that are demonstrated at bifurcations, and is consistent
with the frequency distributions of predicted distal arteriolar perfusion summarized in Figure 6. While
treatment of OZR with phentolamine, TEMPOL or SQ-29548 all exhibited the ability to partially restore
the washout kinetics to levels determined in LZR, combined therapy, which would result in an improved
ls of the networks, resulted in the greatest restoration of the
tracer washout kinetics. One particularly intriguing element of the present study was also revealed
through the use of the tracer washout approach. Given that the mean transit times for tracer washout was
at least 15 seconds under all conditions, despite arteriolar perfusion velocities that would suggest a more
rapid tracer appearance, this suggests that a significant dispersion of the tracer may have also occurred
across the capillary beds and within the post-capillary venular networks. While alterations to venular
function have been unexplored in this model, interrogating how alterations to venular reactivity and
hemodynamics can impact perfusion responses may represent an exciting area for future investigation.
The reader is directed to our computational modeling manuscript (39), where these tracer washout
kinetics are analyzed using a computational model for microvascular perfusion distributions in OZR
versus LZR skeletal muscle, revealing additional insights into network flow distributions associated with
these washout data.

a substantially increased heterogeneity in blood flow distribution within the distal microcirculation of the
skeletal muscle of OZR, is strikingly relevant to the concept of the ‘network Fahraeus effect’ described by
Pries et al. in the late 1980s (33).

As a brief summary, the non-uniform distribution of perfusion at

successive bifurcations within a microvascular network, contributes to a reduction in the mean
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microvascular hematocrit (HMV) measured within the distal microcirculation and capillaries (12, 28). This
process is distinct from the classically described ‘vessel Fahraeus effect’, wherein the differential mean
velocities of plasma and erythrocytes within individual microvessels causes a reduction in the
instantaneous ‘tube’ hematocrit within a microvessel (4, 27). However, the combined influence of the
normal contributing mechanisms to hematocrit reduction within the microcirculation and the effects of an
MV

within

OZR versus LZR that could contribute to the impaired muscle fatigue resistance demonstrated in our
previous studies (15, 20). It is important to state that the results from present study do not account for the
effects of plasma skimming at bifurcations, inherent within the network Fahraeus effect (33), on our
measurements of arteriolar blood flow and that this process may have impacted the washout kinetics of
125

I-albumin in an uncontrolled fashion (as this is an intravascular tracer). Bearing this in mind, further

studies will be required to interrogate the speculative argument outlined above as well as the potential
impact of targeted interventions in improving HMV in OZR.
In keeping with this concept, the results from a several earlier studies resulted in a competing
argument regarding the degree of heterogeneity in capillary perfusion. While results from Tyml’s group
suggested that capillary perfusion heterogeneity was reduced with elevated metabolic demand and the
inherent vasodilation, suggesting a significant, yet unidentified, control mechanism (36), results from
Duling’s group did not support this concept, suggesting that capillary perfusion heterogeneity was not a
controlled variable in skeletal muscle (10).

The results of the present study may be conservatively

interpreted as supporting the former argument, where treatment with phentolamine in OZR increased flow
and narrowed the perfusion frequency distribution (Table 3). Further, as an improvement to endothelial
function in OZR following treatment with TEMPOL and/or SQ-29548 also decreased perfusion
heterogeneity, this also suggests that the normal vascular and endothelial function may contribute to the
regulation of capillary perfusion heterogeneity. However, as these previous studies (10, 36) utilized a
metabolic stimulus as the primary intervention where the current study was conducted in resting muscle,
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additional experiments must be performed to provide for a stronger argument regarding the degree of
control over capillary perfusion heterogeneity.
The results of the present study provide for a new conceptual framework with regard to the study
of PVD in the metabolic syndrome.

Foremost, these results highlight the critical importance of

integration across levels of resolution in efforts to interrogate complex disease states. While previous
work has identified multiple signaling pathways and elements that may contribute to specific indices of
vascular dysfunction (2, 29, 30, 32), there has been a limited effort to determine how these actually
impact perfusion responses in specific vessels (16, 41) and almost no study of how these integrate to
produce an impaired perfusion response across an entire network. A description of network flow

generation, can help to reveal specific mechanistic contributors to PVD, including alterations to
adrenergic constriction, vascular oxidant stress and increased actions of TxA2.

This new conceptual

framework is strongly predictive of the most translationally relevant outcomes associated with
amelioration of PVD, and will be useful in designing and interpreting future studies of PVD in the
metabolic syndrome.
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Table 1. Baseline characteristics of ~17 week-old LZR and OZR used in the present study. * p<0.05
versus LZR. Data are presented as mean±SE.
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LZR (n=26)

OZR (n=102)

Mass (g)

3668

68411*

MAP (mmHg)

101±5

124±6*

[Glucose]plasma (mg/dl)

111±10

184±14*

[Insulin]plasma (ng/ml)

2.0±0.4

9.4±1.1*

[Cholesterol]plasma (mg/dl)

78±9

138±12*

[Triglycerides]plasma (mg/dl)

84±11

348±19*

[Nitrotyrosine]plasma (ng/ml)

14±4

48±8*
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Table 2.

ity (VRBC;

mm/s), and volume perfusion within the arteriole (Q; nl/s). * p<0.05 versus LZR; † p<0.05 versus OZR. Data are presented as mean±SE; -P
represents treatment with phentolamine, -T represents treatment with TEMPOL, -SQ represents treatment with SQ-29548, -LN represents
treatment with L-NAME; with combinations representing treatment with multiple agents.

LZR

OZR

O-P

O-T

O-SQ

O-LN

O-PT

O-PSQ

O-PLN

O-TLN

O-TSQ

O-PTSQ

94±4

85±6

92±3

87±6

88±5

84±6

93±3

93±4

90±4

86±3

86±4

93±3

56±5

46±6

48±5

45±6

49±7

38±6*

52±6

53±5

46±5

48±5

48±4

53±5

Q

245±14

165±20*

200±15

169±14*

186±9*

134±15*

219±6†

224±14†

183±13*

175±13*

176±14*

227±17†

ID

75±4

66±5

72±3

69±6

68±6

64±5

73±4

74±4

71±5

67±6

69±5

74±4

40±6

35±5

40±5

36±6

36±5

32±4

39±5

39±4

36±6

37±5

38±6

40±4

Q

112±10

74±12*

100±9

84±9*

82±5*

65±6*

102±5

105±8

89±9

82±11*

89±12

108±6†

ID

53±4

48±7

50±5

53±6

53±5

47±6

52±5

53±5

48±5

52±5

53±6

53±5

20±4

14±3

17±4

14±3

14±3

12±3

18±3

18±4

15±4

12±3

14±4

20±2

Q

28±4

16±4*

21±3

19±4

19±3

13±3*

24±5

25±5

17±3

16±3

19±4

28±4*

ID

36±4

30±3

31±3

33±5

32±4

28±3

34±5

34±4

29±4

32±5

35±4

35±3

12±3

8±2

12±3

9±2

10±3

8±2

11±2

12±2

8±2

9±2

9±2

12±2

Q

7.8±1.9

3.7±1.5

5.5±1.7

4.7±1.1

4.8±1.3

3.1±0.8*

6.1±1.6

6.6±1.3

3.5±0.9

4.3±1.2

5.5±1.4

7.2±1.6

ID

21±3

18±3

18±2

20±3

19±3

18±3

19±2

20±3

18±2

19±3

19±2

20±2

7±1

4±1

5±2

4±1

4±1

3±1

6±2

7±2

5±2

5±2

5±1

7±1

1.5±0.3

0.7±0.2*

0.8±0.2

0.8±0.2

1.1±0.3

1.3±0.2

0.8±0.2

0.8±0.2

0.8±0.3

1.4±0.3

ID
1A VRBC

2A VRBC

3A VRBC

4A VRBC

5A VRBC
Q

0.7±0.2* 0.5±0.2*
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Table 3. Statistical analysis of the individual frequency distributions of predicted distal arteriolar perfusion heterogeneity presented in Figure 6.
Data are presented for variance, skewness, kurtosis and ranges of the individual distributions, as well as the quartiles and the inter-quartile
difference (IQ Diff.). Results from the Kruskal-Wallis test indicated that there are significant differences across the different distributions
(p<0.001). -P represents treatment with phentolamine, -T represents treatment with TEMPOL, -SQ represents treatment with SQ-29548, -LN
represents treatment with L-NAME; with combinations representing treatment with multiple agents.

LZR

OZR

O-P

O-T

O-

O-

O-

O-

O-

O-

O-

O-

SQ

LN

PT

PSQ

PLN

TLN

TSQ

PTSQ

Variance

0.015

0.384

0.195

0.086

0.106

0.298

0.026

0.024

0.204

0.070

0.070

0.013

Skewness

0.319

1.678

1.131

0.673

0.744

1.470

0.422

0.407

1.175

0.631

0.555

0.302

Kurtosis

-

4.193

1.625

0.171

0.311

3.168

0.033

0.009

1.829

0.184

0.083

0.183

-0.104

Range

0.690

4.210

2.590

1.525

1.705

3.590

0.918

0.888

2.716

1.427

1.280

0.653

Minimum

0.706

0.166

0.291

0.469

0.430

0.206

0.632

.6418

0.278

0.495

0.526

0.722

Maximum

1.397

4.376

2.881

1.994

2.135

3.795

1.551

1.530

2.994

1.921

1.806

1.375

25

0.914

0.571

0.687

0.783

0.755

0.617

0.878

0.895

0.697

0.800

0.795

0.918

50

0.994

0.853

0.916

0.967

0.959

0.883

0.990

0.991

0.912

0.975

0.975

0.996

75

1.081

1.275

1.223

1.194

1.216

1.263

1.117

1.098

1.194

1.187

1.195

1.082

0.167

0.704

0.536

0.411

0.461

0.646

0.239

0.203

0.497

0.387

0.400

0.164

Percentiles

IQ Diff. (75-25)
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FIGURE LEGENDS
Figure 1. Schematic representation of the in situ cremasteric arteriolar bifurcation used for assessing ‘parent’
and ‘daughter’ arteriolar mechanical and hemodynamic/perfusion responses to pharmacological challenge.
Open arrows represent parent or daughter arteriolar diameter in response to a specific condition; filled arrows
represent parent or daughter arteriolar erythrocyte velocity in response to a specific challenge. These data are

text for additional details.

Figure 2. Micr
arterioles within in situ cremaster muscle. Data are presented as mean±SE for LZR under control conditions
and in OZR under control conditions and following treatment with the adrenoreceptor antagonist
phentolamine (P), the antioxidant TEMPOL (T), the PGH2/TxA2 receptor blocker SQ-29548 (SQ), the nitric
oxide synthase inhibitor L-NAME (LN) or combinations of these agents. Panel A presents data describing
the magni

-2A bifurcation under the specific experimental conditions and Panel B presents

pharmacological challenge. Please see text for additional details. For Panel A, * p<0.05 vs. LZR; † p<0.05
vs. OZR. For Panel B, * p<0.05 versus no change.

Figure 3.
arterioles within in situ cremaster muscle. Data are presented as mean±SE for LZR under control conditions
and in OZR under control conditions and following treatment with the adrenoreceptor antagonist
phentolamine (P), the antioxidant TEMPOL (T), the PGH2/TxA2 receptor blocker SQ-29548 (SQ), the nitric
oxide synthase inhibitor L-NAME (LN) or combinations of these agents. Panel A presents data describing
the ma

-3A bifurcation under the specific experimental conditions and Panel B presents
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pharmacological challenge. Please see text for additional details. For Panel A, * p<0.05 vs. LZR; † p<0.05
vs. OZR. For Panel B, * p<0.05 versus no change.

Figure 4.
arterioles within in situ cremaster muscle. Data are presented as mean±SE for LZR under control conditions
and in OZR under control conditions and following treatment with the adrenoreceptor antagonist
phentolamine (P), the antioxidant TEMPOL (T), the PGH2/TxA2 receptor blocker SQ-29548 (SQ), the nitric
oxide synthase inhibitor L-NAME (LN) or combinations of these agents. Panel A presents data describing
-4A bifurcation under the specific experimental conditions and Panel B presents
the % recovery (to the level deter
pharmacological challenge. Please see text for additional details. For Panel A, * p<0.05 vs. LZR; † p<0.05
vs. OZR. For Panel B, * p<0.05 versus no change.

Figure 5. Microvascular per
arterioles within in situ cremaster muscle. Data are presented as mean±SE for LZR under control conditions
and in OZR under control conditions and following treatment with the adrenoreceptor antagonist
phentolamine (P), the antioxidant TEMPOL (T), the PGH2/TxA2 receptor blocker SQ-29548 (SQ), the nitric
oxide synthase inhibitor L-NAME (LN) or combinations of these agents. Panel A presents data describing
the 4A-5A bifurcation under the specific experimental conditions and Panel B presents

pharmacological challenge. Please see text for additional details. For Panel A, * p<0.05 vs. LZR; † p<0.05
vs. OZR. For Panel B, * p<0.05 versus no change.
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Figure 6. Predicted perfusion distributions in the distal microcirculation of skeletal muscle of LZR and
OZR under the conditions of the present study. Frequency distributions are calculated based on an eight
in
situ cremaster muscle presented in Figures 2-5. Individual panels present the distribution of perfusion
across of 256 (28) parallel arterioles under each experimental condition as a result of the simulation of a
dichotomous branching network. Please see text for additional details.

Figure 7. Data describing the washout of 125I-albumin from the in situ gastrocnemius muscle of LZR and
OZR under the conditions of the present study. Data are presented as mean±SE for LZR (n=10) under
control conditions and OZR under control conditions (total n=28) and following intravenous treatment with
the adrenoreceptor antagonist phentolamine (P; n=10), the antioxidant TEMPOL (T; n=9), the PGH2/TxA2
receptor blocker SQ-29548 (SQ; n=9), or for combinations of these agents (n=8-10 for each).

Figure 8. Data (presented as mean±SE) describing the four moments of the washout of 125I-albumin from
the in situ gastrocnemius muscle of LZR and OZR under the conditions of the present study. Data are shown
for the mean transit time of the washout (Panel A), the relative dispersion of the washout (RD; Panel B), the
distribution skewness (Panel C) and kurtosis (Panel D). Please see text for details. * p<0.05 vs. LZR; †
p<0.05 vs. OZR.
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Conceptual Framework
The third chapter is entitled “Spatial Heterogeneity in Skeletal Muscle Microvascular Blood Flow
Distribution is Increased in the Metabolic Syndrome”. It followed from the above paper, and was based
on the data suggesting that the inability of the OZR skeletal muscle to resist fatigue lies within
dysfunctional alpha-adrenergic behavior and endothelial dysfunction predominantly driven by oxidant
stress and altered AA metabolism. However, these mechanisms suggest spatial differences, thus this paper
uses the in situ cremaster preparation and the in situ blood perfused hindlimb with I125 labeled albumin to
examine an entire microvascular network with intact blood flow. It allowed for the determination of blood
flow distributions at bifurcations at different levels of resolution. In the OZR it identified an increased
perfusion distribution compared to the LZR, but revealed that the mechanisms that affect the distribution
are spatially distinct. The proximal microcirculation perfusion distribution appears largely impacted by
alpha-adrenergic dysfunction, while the distal microcirculation perfusion distribution is altered by oxidant
stress and TxA2. The result of these impairments to perfusion is a “low flow” and a “high flow” pathway
that it iterated at each bifurcation across the entire microvasculature network. The indicator solution
washout analysis was included to ensure that the results of the high resolution bifurcation study was not a
result of selection bias, as the I125 albumin is an intravascular tracer used for integrated assessment of
network function. The results indicate significant disparity between the mean transit time, dispersion,
skewness, and kurtosis of the OZR compared to the LZR, which suggestively confirm the “high/low
flow” pathways at bifurcations and matches previous predictive models.
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ABSTRACT
A key clinical outcome for peripheral vascular disease (PVD) in patients is a progressive decay in skeletal
muscle performance and its ability to resist fatigue with elevated metabolic demand.

We have

demonstrated that PVD in obese Zucker rats (OZR) is partially due to increased perfusion distribution
heterogeneity at successive microvascular bifurcations within skeletal muscle.

As this increased

heterogeneity () is longitudinally present in the network, its cumulative impact is a more heterogeneous
distribution of perfusion between terminal arterioles than normal, causing greater regional tissue
ischemia. To minimize this negative outcome, a likely compensatory mechanism against an increased 
should be an increased temporal switching at arteriolar bifurcations to minimize downstream perfusion
deficits. Using in situ cremaster muscle, we determined that temporal activity (the cumulative sum of
absolute differences between successive values of , taken every 20 seconds) was lower in OZR than in
control animals, and this difference was present in both proximal (1A-2A) and distal (3A-4A) arteriolar
bifurcations.

While adrenoreceptor blockade (phentolamine) improved temporal activity in 1A-2A

arteriolar bifurcations in OZR, this was without impact in the distal microcirculation, where only
interventions against oxidant stress (TEMPOL) and thromboxane A2 activity (SQ-29548) were effective.
Analysis of the attractor for  indicated that it was not only elevated in OZR, but also exhibited severe
reductions in range, suggesting that the ability of the microcirculation to respond to any challenge is
highly restricted, and may represent the major contributor to the manifestation of poor muscle
performance at this age in OZR.

Key Words: rodent models of obesity; microcirculation; skeletal muscle blood flow regulation; models of
peripheral vascular disease; blood flow heterogeneity; vascular dysfunction
INTRODUCTION
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With ongoing study, there is increasing appreciation that the transition from ‘healthy’ physiology
to disease states represents a change in the overall system of control from an existing normal structure
(46). It is also generally unclear whether this transition represents a failure of the ‘healthy’ system or
evolving compensations to attempt to optimize the most critical biological outcomes despite progression
of a challenged environment (38, 57).

For this reason, a detailed understanding of which major

contributing processes to an outcome are altered with pathology and the extent for which these are
compensated is critical for developing appropriate therapeutic interventions. Failure to elucidate both the
key sites of impairment and the compensatory mechanisms, as well as how these impact functional
outcomes, has resulted in poorly targeted interventional measures.
While the existing literature contains extensive prior interrogation into the effects of
atherosclerotic peripheral vascular disease on perfusion and performance outcomes in multiple model
systems as well as the identification of many putative mechanistic contributors to plaque/lesion
development (1, 9, 20, 27, 30, 39), investigation into the impact of non-atherosclerotic peripheral vascular
disease (PVD) has received a much more limited investment. While underrepresented to date, this is an
exceedingly important area of investigation, as a growing body of evidence suggests that an increasing
number of human subjects are afflicted with the symptomology of PVD in the absence of overt
plaque/lesion development (12, 19, 31, 44, 45).
Based on its origin in a dysfunctional leptin receptor gene, destroying the satiety reflex, the obese
Zucker rat (OZR) experiences a chronic hyperphagia, developing severe obesity, a progressive worsening
of glycemic control and plasma lipid profiles and, ultimately, the development of moderate hypertension
(32, 37). The importance of the OZR model for studying non-atherosclerotic PVD is considerable, as the
genesis of the pathological state lies within the leptin resistance-induced hyperphagia, which is found in
the human population (53, 56).

Further, the severity of the elevated risk factors for a negative

cardiovascular outcome has repeatedly been demonstrated to be comparable to that determined in
afflicted patients, and these animals do not develop atherosclerotic lesions.
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Recent study has provided clear and compelling evidence that impairments to skeletal muscle
performance that are associated with development of non-atherosclerotic PVD in OZR are not adequately
predicted by basic indices such as the mechanical responses of resistance arterioles to stimuli or by bulk
blood flow responses to skeletal muscle (25).

Rather, we have recently demonstrated that a defining

characteristic of non-atherosclerotic PVD in OZR skeletal muscle is an increasingly asymmetric blood
flow distribution at successive microvascular bifurcations, resulting in pronounced heterogeneity of
perfusion across the distal arterioles within the network (24, 59).

While this increased spatial

heterogeneity of perfusion distribution was improved by interventions against reactive oxygen stress, the
actions of thromboxane, and altered function within adrenergic vasoconstriction (24, 59), the question of
the system compensation for this increased perfusion heterogeneity in OZR is entirely unknown.
Conceptually, a likely compensation for the increased spatial heterogeneity of perfusion in the
microcirculation of OZR could be via increased temporal switching at arteriolar bifurcations. As the
spatial heterogeneity between parallel daughter arterioles would create relative degrees of downstream
ischemic signals between the parallel perfused regions, a compensation that resulted in increased temporal
switching between ‘high flow’ and ‘low flow’ daughter arterioles would help to minimize the severity and
duration of the resulting ischemic regions and could act to maintain muscle performance to the greatest
possible extent.
Given this conceptual framework, the purpose of the present study was to determine the degree of
temporal switching at arteriolar bifurcations within the resting skeletal muscle microcirculation of OZR
versus LZR, the extent to which this acts as a compensatory physiological mechanism to the increased
spatial perfusion heterogeneity and to determine the major contributing mechanisms to differences
between the two conditions. This study tested the hypothesis that temporal switching at arteriolar
bifurcations is increased in skeletal muscle of OZR as a means for compensating for the increased spatial
perfusion heterogeneity and helping to maintain skeletal muscle performance at optimal levels despite the
evolving pathological state.
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MATERIALS AND METHODS
Animals: Male lean (total n=20; Harlan) and obese Zucker rats (total n=38; fa-/fa-; Harlan) were fed
standard chow and drinking water ad libitum and were housed in the animal care facility at the West Virginia
University Health Sciences Center or the Medical College of Wisconsin. All protocols received prior IACUC
approval. At ~17 weeks of age, rats were anesthetized with injections of sodium pentobarbital (50 mg/kg,
i.p.), and received tracheal intubation to facilitate maintenance of a patent airway. In all rats, a carotid artery
and an external jugular vein were cannulated for determination of arterial pressure and for infusion of
supplemental anesthetic and pharmacological agents, as necessary. Any animal in which mean arterial
pressure was found to be below 85 mmHg, or where MAP had decreased by more than 15% from that
following this initial surgery (without any pharmacological intervention) was not used in the present study.
Blood samples were drawn from the venous cannula for determination of glucose and insulin concentrations
(Millipore; Billerica, MA) as well as cholesterol/triglyceride levels (Wako Diagnostics; Richmond, VA), and
nitrotyrosine (Oxis International; Foster City, CA). Unless otherwise noted, all drugs and chemicals were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Preparation of In Situ Cremaster Muscle: In each rat (LZR n=20; OZR n=38), an in situ cremaster
muscle was prepared for intravital microscopy (2, 26, 35), and was continuously superfused with
physiological salt solution (PSS) equilibrated with a 5% CO2-95% N2 gas mixture, maintained at 35C, as
it flowed over the muscle. Volume flow rate was ~3.0 ml/min. The ionic composition of the PSS was as
follows (mM): NaCl 119.0, KCl 4.7, CaCl2 1.6, NaH2PO4 1.18, MgSO4 1.17, NaHCO3 24.0, and
disodium EDTA 0.03. After a 30 minute period of equilibration following the surgical preparation,
arterioles and bifurcations within two distinct “bifurcation categories” were selected for investigation: 1)
~100 m ‘parent’ to ~80 m ‘daughters’ (1A-2A) and 2) ~60 m ‘parent’ to ~40 m ‘daughters’ (3A4A). Arterioles/bifurcations were selected based on the following criteria: 1) distance from any site of
incision, 2) presence of significant vascular tone (assessed by brisk dilator response to challenge with 10-3
M adenosine), 3) clearly discernible walls, 4) a rapid and stable level of erythrocyte perfusion, and 5) the
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presence of two clearly defined ‘daughter’ branches that also met criteria 1-4. Please see Figure 1 for a
schematic representation (also reference 24).
The mechanical (using on-screen videomicroscopy) and perfusion (using optical Doppler
velocimetry) responses of both the ‘parent’ and ‘daughter’ arterioles within a bifurcation class were
assessed under resting conditions within the cremaster muscle of each rat. All procedures were performed
under control conditions in LZR and OZR, and following treatment of the in situ cremaster muscle with
the anti-oxidant TEMPOL (10-3 M), the TxA2 receptor antagonist SQ-29548 (10-4 M), and/or the 1/2
adrenergic receptor antagonist phentolamine (10-5 M); within the superfusate solution. All treatments to
the cremaster were of a minimum of 40 minutes duration prior to any subsequent experimental
manipulation/data collection.
Interrogation of Arteriolar Bifurcations: Within each animal, one 1A-2A bifurcation and one 3A-4A
bifurcation was studied within the arteriolar network. For an individual measurement, arteriolar diameter
and erythrocyte velocity were monitored for 5 minutes, with measurements taken every 20 seconds. All
arterioles and bifurcations were selected on the basis of the criteria outlined above and were placed into
their categories by size rather than by strict branch number within the network.
In order to maintain preparation and collected data quality, no cremaster muscle was exposed to
all interventions and combinations listed above. In addition to the collection of responses under control
conditions, individual cremaster preparations were exposed to a maximum of four interventions, each
separated by ~30 minutes of washout. Treatment or washout effectiveness was verified by determining
abolition or recovery of mechanical responses following challenge with appropriate agonists (e.g., the 1
adrenergic antagonist phenylephrine, the stable TxA2 mimetic U-46619, and the endothelium-dependent
dilator agonist acetylcholine for the appropriate initial treatments). Maximum experimental duration from
preparation to termination was approximately four hours, after which time all animals were humanely
euthanized by an intravenous overdose of anesthetic followed by a bilateral pneumothoracotomy, as per
approved IACUC protocols.
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Data and Statistical Analyses: Arteriolar perfusion in both parent and daughter vessels within in situ
cremaster muscle of LZR and OZR was calculated as:
(

)(

)(

)

where Q represents arteriolar perfusion (nl•s-1), V represents the measured red cell velocity from the
optical Doppler velocimeter (mm•s-1; with V/1.6 representing an estimated average velocity assuming a
parabolic flow profile; Ref. 18), and r represents arteriolar radius (m; Ref. 4).
The total volume perfusion in the daughters was determined as the sum of the individual perfusion
rates, and the proportion of flow within each was determined as the quotient of the individual branch divided
by the total.  is defined as the ratio of the greater of the two flows in the daughter vessel to the total flow in
the parent vessel. As an example, if flow distribution was homogeneous between daughters,  for that
bifurcation would be 0.5 in both daughter arterioles, while if the proportion of flow in one daughter arteriole
was 60%, for that bifurcation would be 0.6, with flow distribution being 0.6 in the ‘high perfusion’ arteriole
and 0.4 in the ‘low perfusion’ arteriole (Figure 1, and Ref. 6).
Monitoring  throughout the observation period and analyzing those resulting data used three initial
approaches. The first of these was simply to determine the mean±SE of the individual measurements
throughout the 5 minute observation window, providing the mean value for . However, this is clearly not
sufficiently informative in terms of understanding the temporal behavior for  at a bifurcation. The second
approach was to determine the cumulative change in  from each of the 15 successive measurements:

∑(

( )

(

))

where  represents the perfusion distribution at any given bifurcation and t represents the measurement time
from 1 (initial) to 15 (final). While these data can provide us with evidence of broader changes in  with
longer durations, it was apparent that a more sensitive marker is needed to provide sufficient insight into
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temporal switching at an arteriolar bifurcation. As such, the final approach is to summate the absolute values
of the differences in  from one time point to the next to provide for a superior index of total activity:

∑

(

( )

(

))

This final index (summating absolute difference in ), will provide insight into the total temporal switching at
any arteriolar bifurcation within the data collection window.
In order to determine the effectiveness of any intervention on improving the behavior of  over the
data collection window in OZR, the values for the  (cumulative, absolute differences) that were collected for
arteriolar bifurcations in LZR under control conditions (A) were set as the overall control value. As such, the
impact of pathology (development of the metabolic syndrome) is determined from the data collected in OZR
(

under control conditions (B) and is the absolute difference between these two values:

).

The extent to which any intervention in OZR can improve normal behavior is given by the value of 
(cumulative, absolute) following the intervention (C), and is represented by:

(

). Given this,

the percent effectiveness of any intervention in restoring the normal behavior of  at a bifurcation in OZR is
provided by:

( ⁄ )

.

An attractor is generally defined as the set of conditions towards which a given variable evolves over
time. To a significant extent, this can be considered as the representation of the behavior of a dynamic
system over a period of time, and this can be extremely useful in understanding the limits of a system (i.e.,
what behaviors are either not possible, not generally attainable or are extremely unlikely) and the effects on
system behavior (either beneficial or detrimental) subsequent to an imposed intervention.

The most

informative manner in presenting an attractor is as an iterated map, where the current state of the parameter
under study is plotted at a given moment, and then its change in position re-plotted at the next time interval.
This process is iterated repeatedly, to the conclusion of the data set, and the shape and location of the attractor
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on the co-ordinate system becomes evident.

This approach also facilitates comparisons between

experimental conditions and the impact these have on the location and shape of the attractor.
All data throughout the manuscript are presented as mean±SE. Statistically significant differences in
measured and calculated parameters were determined using a one sample t-test (differences from zero),
Student’s t-test or analysis of variance (ANOVA) with Student-Newman-Keuls post-hoc test used as needed.
In all cases, p<0.05 was taken to reflect statistical significance.
RESULTS
Table 1 presents the baseline characteristics of animals used in the present study. By ~17 weeks
of age, OZR demonstrated striking obesity and had a significantly higher mass than LZR. Further, OZR
exhibited statistically significant elevation in mean arterial pressure, and both plasma insulin and
nitrotyrosine concentrations.

Data describing the dimension and perfusion characteristics of the

cremasteric arteriolar bifurcation segments (described above) under the conditions of the present study are
summarized in Table 2. These data clearly demonstrate general differences between arteriolar diameter
and perfusion characteristics that are distributed longitudinally throughout the cremasteric
microcirculation under the conditions of the present study.
Figure 2 presents representative data describing the distribution of the magnitude of  and its
temporal behavior across 1A-2A (Panels A and B, respectively) and 3A-4A (Panels C and D,
respectively) arteriolar divisions. As suggested by these data, in addition to a shift in the frequency
distribution of  between LZR and OZR at both microvascular divisions, the changes in  (measured
every 20 seconds over the course of 5 minutes) were less extensive in both proximal and distal
bifurcations of the resting cremaster muscle microcirculation of OZR as compared to LZR.
Proximal Resistance Arterioles: The summarized results of the average magnitude of  at 1A-2A
arteriolar bifurcations over the observation period are presented in Figure 3. In LZR (Panel A),  was
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approximately 0.51 under control conditions, and was not altered by acute pharmacological intervention.
In contrast, average  over the 5 minute period in OZR (Panel B) was much higher, approximately 0.58
under control conditions. While interventions containing phentolamine (regardless of the presence of any
other substance) reduced average to levels determined in LZR, treatment against either the increased
TxA2 production (SQ-29548) or the elevated vascular oxidant stress (TEMPOL) in OZR were not
effective, resulting in minimal changes to .
Data describing the changes in  in 1A-2A bifurcations between LZR and OZR over the 5 minute
observation window are summarized in Figure 4. When presented as the cumulative change in , neither
LZR (Panel A) nor OZR (Panel B) exhibited a difference between strains or a clear pattern in terms of the
cumulative change in  within a strain. However, when the cumulative changes in  are presented as the
sum of the absolute changes, striking differences are evident. While a clear reduction in the cumulative
change in  (absolute) was evidence in OZR (Panel D) as compared to LZR (Panel C), blockade of
adrenoreceptors (alone or with any other pharmacological intervention) in 1A-2A bifurcations in LZR
reduced activity at the bifurcation. In contrast, treatment of elevated oxidant stress with TEMPOL or
blockade of TxA2 with SQ-29548 has no discernible impact. In 1A-2A bifurcations from OZR, treatment
with phentolamine (either alone or with TEMPOL and/or SQ-29548) significantly increased the
cumulative change in  (absolute) over the data collection window (Panel D).

Similarly to LZR,

treatment with TEMPOL and/or SQ-29548 in the absence of phentolamine did not have a significant
impact.
Distal Resistance Arterioles: Comparable to data presented for proximal resistance arterioles, the average
 for 3A-4A arteriolar bifurcations over the 5 minute period was ~0.5 in LZR under control conditions
(Figure 5, Panel A) and this was elevated in OZR (Panel B). However, while treatment interventions
were without effect in LZR, application of either TEMPOL or SQ-29548 in OZR significantly reduced
mean  toward 0.5. In contrast to the results from more proximal resistance arterioles,  was largely
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unaffected by phentolamine treatment and interventions targeted at rectifying endothelial dysfunction
were required in order to cause a significant restoration of .
Figure 6 presents the cumulative changes in  over the 5 minute period in 3A-4A arteriolar
bifurcations from LZR (Panels A and C) and OZR (Panels B and D).

When the changes in  are

presented as simple accumulation, there were no significant differences between LZR (Panel A) and OZR
(Panel B) or within a strain as a result of any intervention. However, when the changes in  are summated
as absolute differences, clear differences were identified. In 3A-4A arteriolar bifurcations of LZR (Panel
C), acute treatment with phentolamine reduced the accumulated changes to , while the presence of
TEMPOL and/or SQ-29548 resulted in minimal total changes or marginal change (when applied in
combination with each other or with phentolamine). In contrast, application of TEMPOL and/or SQ29548 significantly improved the cumulative changes to  (absolute) in 3A-4A arteriolar bifurcations of
OZR, while the effects of phentolamine application were muted (Panel D).
Effects of Adenosine: To simulate the impact of elevated metabolic demand on the temporal stability of
 throughout the cremaster muscle microcirculation, increasing concentrations of adenosine were added to
the preparation superfusate. While application of adenosine had minimal impact on average  in LZR, it
reduced average  in OZR, at both 1A-2A (Panel A) and 3A-4A (Panel C) bifurcations to levels that were
very similar to that determined in LZR, with the greatest impact being observed with the highest level of
adenosine (Figure 7). Adenosine did not impact the cumulative change in  over the 5 minute period in

summated as absolutes, application of increasing concentrations of adenosine reduced temporal activity in
LZR at both 1A-2A (Panel B) and 3A-4A (Panel D) bifurcations, although it had minimal impact on
activity in the bifurcations of OZR (Panels B and D).
Effectiveness of Interventions in Restoring Normal Behavior: Figure 8 summarizes the impact of the
interventions on restoring normal temporal activity at 1A-2A (Panel A) and 3A-4A (Panel B) arteriolar
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bifurcations in OZR (where the activity at those bifurcation levels in untreated LZR is defined as
control/normal). As shown in Panel A, while there is a significant recovery in function with treatment
with the adrenoreceptor antagonist alone, combined therapy of phentolamine with the agents targeted at
improving endot
the proximal arteriolar bifurcations of OZR. Conversely, the reverse pattern was evident for distal
arteriolar bifurcations of OZR, as treatment with SQ-29548 and/or TEMPOL resulted in significant

in a further marginal improvement to this outcome.
Establishment of a New Attractor for PVD: Figure 9 presents the attractor

-2A arteriolar

bifurcations in cremaster muscle of LZR and OZR (control conditions). As show in Panel A, the attractor

tment with phentolamine (Panel B) was effective in restoring the magnitude of
the attractor in OZR compared to that in LZR, although range remained restricted. In contrast, treatment
of the cremasteric network with TEMPOL and/or SQ-29548 was of minimal benefit in restoring the
attractor in OZR to that in LZR (Panel C). However, combined treatment with phentolamine and
TEMPOL/SQ-29548 almost completely restored the magnitude and the shape of the attractor in OZR to
that in LZR. This situation was reversed in distal arteriolar bifurcations of OZR and LZR (Figure 10), as
the shift in the attractor for OZR versus LZR under control conditions (Panel A) was much more strongly
impacted by treatment with TEMPOL and/or SQ-29548 (Panel C) than with phentolamine (Panel B);
although combined treatment with phentolamine and TEMPOL/SQ-29548 still resulted in near complete
restoration of the attractor shape and magnitude determined in LZR (Panel D).
The effects of increasing adenosine concentration on the attractor in arteriolar bifurcations of
OZR are summarized in Figure 11.

In both proximal (Panel A) and distal (Panel B) arteriolar

bifurcations, treatment with high concentrations of adenosine (10-3M) restored the attractor magnitude,
but not the full extent of the shape. Lower concentrations of adenosine (10-7 or 10-5M) were without

137

concentrations of adenosine, there was a less heterogeneous distribution of perfusion at bifurcations, but

DISCUSSION
It has long been understood that the development of non-atherosclerotic PVD, with its implicit
failure of appropriate matching of blood perfusion to meet requisite metabolic demand, is associated with
a severely compromised ability of the skeletal muscle to maintain performance (i.e., developed tension
levels; refs. 19, 44). However, using the OZR model of the metabolic syndrome, it has been clearly
demonstrated that blood-perfused skeletal muscle rates of fatigue are increased as compared to LZR, and
that this compromised performance is not simply a function of global ischemia (25). Rather, treatment
with an adrenoreceptor antagonist and a substantial restoration of functional hyperemia, muscle fatigue
rates and oxygen uptake (VO2) remained compromised in OZR as compared to LZR. It was only after
combined treatment with both the adrenoreceptor antagonist and interventions ameliorating endothelial
dysfunction (the anti-oxidant TEMPOL and/or the PGH2/TxA2 receptor antagonist SQ-29548) that muscle
performance and VO2 were improved. These results strongly suggest a spatial divergence with regard to
dysfunction wherein altered adrenoreceptor function primarily impacts bulk perfusion resistance while
altered endothelial function primarily impairs perfusion:demand matching in the distal microvasculature
(25). We have interrogated this spatial divergence in blood flow control in skeletal muscle of OZR and
have determined that a defining characteristic of PVD in this model is an increasingly heterogeneous
distribution of blood flow at successive bifurcations within the arteriolar network (defined by the

strongly predictive of poor muscle performance, it was determined to be longitudinally consistent down
the arteriolar network, and was demonstrated to lead to severe increases in blood flow distribution at the
pre-capillary level in OZR as compared to LZR (24, 59).
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geneity of perfusion
distribution represent a deviation from the normal system behavior identified in microvascular networks
of LZR. However, as with the majority of biological systems, compensatory mechanisms that can
minimize the impact of the increased spatial heterogeneity in perfusion should be present. Logically, the
most likely compensatory mechanism would be an increased temporal ‘switching’ at the individual
bifurcations (an increased rate of change with regard to which daughter represents the ‘high’ or ‘low’

which signals associated with any developed ischemic signals accumulate within a ‘low flow’ branch.
While the nature of these signals is not fully clear at this time, with potential contributors stemming from
the buildup of parenchymal tissue metabolic signals (10, 13, 17, 49), substances released from
increasingly deoxygenated erythrocytes as they pass through the microcirculation (22, 29, 50, 51), or
undefined signals that are propagated along myocyte and/or endothelial communication pathways (3, 7,
21, 55), the general principle appears to be valid regardless of the stimuli involved.
The data presented in this study refute our general
time at both 1A-2A (Figures 3/4) and 3A-4A (Figure 5/6) arteriolar bifurcations in resting skeletal muscle
of OZR were significant reduced as compared to levels determined in LZR. This is a particularly striking
observation, as it clearly suggests that not only does a change in temporal switching at arteriolar

the reduction in temporal switching actually entrenches the negative outcomes for perfusion distribution

blunting of temporal activity in arteriolar bifurcations of OZR could be ameliorated.

In proximal

resistance arterioles, treatment of the resting cremaster muscle with phentolamine, to remove alterations
to the distribution of adrenergic constriction throughout the network, significantly increased the
fied in the distal microcirculation, where adrenoreceptor
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correcting endothelial dysfunction (TEMPOL and/or SQ-29548) had minimal impact on the temporal
activity of perfusion distribution at proximal arterioles, but significantly improved this response in more
distal 3Avery similar to that determined for LZR under control conditions. It is particularly compelling that these
interventions, and their sites of greatest impact parallel results in our previous studies with regard to
ng muscle
fatigue resistance and VO2 (24).

Specifically, while treatment with either phentolamine or

TEMPOL/SQ-29548 alone improved select or localized indices of vascular function (with no beneficial
impact on muscle performance), only combined treatment with phentolamine and TEMPOL/SQ-29548
resulted in a widely distributed and significant improvement to muscle perfusion, VO2 and performance
(25). Taken together, this series of observations suggest that, with a combined intervention designed to
remove alterations to adrenergic constriction and endothelial dysfunction in the OZR model of metabolic
syndrome, blood flow hemodynamics at successive arteriolar bifurcations is improved to a condition
which helps to restore the processes of mass transport and exchange in the microcirculation to a level that
allows for a significant improvement to muscle performance. However the extent to which this is
manifested as a change to the total surface area available for exchange in the muscle or an improvement
to erythrocyte distribution within the terminal arterioles and capillary networks remains to be elucidated.
One of the benefits derived from the increased effort of acquiring temporal data is that it can
allow for the determination of an attractor. In essence, an attractor is the set to which a variable will
adhere over time (36, 58). Even following perturbation as a result of an imposed challenge, the variable
will change its behavior over time to return to its attractor if possible (36, 58). In the present experiments,
the attractor for both proximal (1A-2A) and distal (3A-4A) arteriolar bifurcations in LZR exhibited a

both proximal (Figure 9) and distal (Figure 10) arteriolar bifurcations of OZR, where the central region of
the attractor was shifted to ~0.58, with a narrowed range of achieved values. Beyond being an intriguing
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scientific curiosity, this shift in the attractor has critical implications for blood flow control in OZR. The
change in both magnitude and range of the attractor with the development of pathology in OZR indicates
that the ability of arterioles and arteriolar bifurcations to respond to imposed challenges (e.g., changes in
metabolic demand) will be severely compromised as the potential for perfusion redistribution will be
constrained to a more limited set of attainable conditions.

Essentially, the development of non-

atherosclerotic PVD in OZR is defined by a loss of flexibility in the control systems contributing to the
regulation of perfusion distribution in skeletal muscle, thus severely compromising the ability to
effectively adapt to changing conditions. This is a particularly striking outcome and it may represent the
more functionally integrated extension of a similar process identified by Tigno et al. (54) in diabetic
monkeys, where the randomness of arterial vasomotion was found to be dampened with disease
progression. Taken together, it is not simply that we have dysfunction and can identify it in a series of
reduced preparations.

It is that indices of dysfunction in simplified preparations, when integrated,

produce an outcome wherein the pathology is partially defined by an impaired ability of the system to
respond to stressors.
Despite numerous attempts, we were unable to acquire a sufficiently robust data set which

simulator of this condition, we utilized elevated concentrations of adenosine in the preparation

low (10-7M) or moderate (10-5
or the resulting attractor in arteriolar bifurcations of OZR, while superfusion with high concentrations of
adenosine (10-3
restore the range of the attractor (Figure 11). These observations strongly suggest that the arteriolar
networks in OZR may be resistant responding to elevated metabolic demand, until a ‘threshold’ is
reached. Once a sufficient metabolic intensity (or build-up of the appropriate signal) has been attained,
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remains blunted). As we have demonstrated previously (24), this high concentration of adenosine results
in a maximal relaxation of in situ skeletal muscle arterioles in OZR, meaning that the entire vascular

reflect only the impact of the architecture and geometric arrangement of the network, as well as the
intrinsic physical processes associated with blood flow and erythrocyte distribution in vascular networks,
as has been previously studied by Cokelet (14, 15) and Kiani (33), among others (23, 28). As presented
nder these conditions is very similar between LZR and OZR in terms of
magnitude and shape, but with a restricted range.
Given the nature of the data in the present study, attention should be given to the impact of the
method of anesthesia on outcomes and data interpretation. Numerous previous studies have demonstrated
that both inhalational volatile and injectable general anesthetics can impact endothelial function and
vasomotion (16, 41, 48), as well as baroreflex sensitivity and the sympathetic control of vascular tone
(48). As such, either option presents a challenge for data interpretation in the present study, especially
given the complications associated with altered baroreflex control (40, 47), sympathetic output (11, 47),
and endothelial function (25) that has been demonstrated in the obese Zucker rat. While for this research,
we have elected to utilize a barbiturate anesthetic (owing to the time between exposure and data
collection, and to avoid the impact on vasomotion), these are issues that become extremely complicated
and further investigation of the impact of anesthetic regimen on microvascular outomes in models of
increased PVD risk may be warranted.
Obviously, the ultimate outcome for microvascular function, regardless of condition, is the ability
of the networks to adequately support mass transport and exchange under both resting and challenged
conditions. If we assume that the attractors identified for LZR under control conditions are representative
of ‘health’, for the purposes of the present discussion it may be useful to consider this as ‘optimized’ (i.e.,
these attractors describe microvascular networks functioning optimally). Assuming this, the attractors for
OZR would represent the resultant state of the microcirculation under conditions of the metabolic
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syndrome. As such, it is important to estimate how these changes to perfusion distribution would impact
indices such as tissue oxygenation or microvascular hematocrit. While these measurements are outside of
the scope of the current study, previous research efforts can provide some potential insight. In particular,
the work of Pries et al. (42, 43), has identified a ‘network Fahraeus effect’ that can represent a significant
contributor to the ultimate reduction in microvascular hematocrit at successive bifurcations owing to a
disproportionate distribution of flow (and therefore, erythrocytes) at arteriolar bifurcations.

Under

‘control’ conditions, those authors suggested that this alone could cause a reduction in microvascular
hematocrit approaching 20%, with direct implications for tissue oxygenation (8, 52). As the results from

it would be logical to speculate that this would result in an exacerbation of the ‘network Fahraeus effect’,
which, when taken in combination with other contributors to hematocrit reduction (e.g., the ‘vessel
Fahraeus effect’ (15, 43) and other hemo-rheological parameters (5, 23, 34)), would result in a further
reduction of microvascular hematocrit within the networks.

While specific interventions such as

adrenoreceptor blockade and inhibiting the actions of TxA2 could provide some amelioration of this
impairment, based on alterations to the shape of the attractors, only a combined interventional strategy
would be sufficient to cause an improvement to arteriolar network function that would be sufficient to
result in alterations to mass transport and exchange that were large enough to improve muscle fatigue
resistance (25). Further investigation into the impact of these cumulative perfusion abnormalities in the
skeletal muscle microcirculation of OZR could provide us with a far more complete understanding of how
non-atherosclerotic PVD is manifest in this increasingly relevant animal model of the metabolic
syndrome.
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Table 1. Baseline characteristics of ~17 week-old LZR and OZR used in the present study. * p<0.05
versus LZR. Data are presented as mean±SE.

LZR (n=20)

OZR (n=38)

Mass (g)

3579

67610*

MAP (mmHg)

104±4

135±6*

[Glucose]plasma (mg/dl)

106±9

188±12*

[Insulin]plasma (ng/ml)

1.7±0.2

8.8±1.3*

[Nitrotyrosine]plasma (ng/ml)

17±4

53±7*

151

Table 2.

ity (VRBC;

mm/s), and volume perfusion within the arteriole (Q; nl/s). * p<0.05 versus LZR; † p<0.05 versus OZR. Data are presented as mean±SE; -P
represents treatment with phentolamine, -T represents treatment with TEMPOL, -SQ represents treatment with SQ-29548; with combinations
representing treatment with multiple agents.

1A

2A

3A

4A

LZR

OZR

O-P

O-T

O-SQ

O-PT

O-PSQ

O-TSQ

O-PTSQ

ID

95±4

81±5

93±4

83±5

84±6

93±4

94±4

85±5

94±4

VRBC

56±6

42±6

53±6

46±5

44±5

53±5

53±6

47±4

54±5

Q

248±12

135±15*

225±16†

156±13

152±11

225±9†

230±15†

167±11

234±12†

ID

70±5

60±6

67±5

64±4

63±5

68±4

68±5

64±4

69±4

VRBC

50±4

34±6

47±6

38±6

36±4

46±5

48±4

41±5

49±5

Q

120±12

60±7*

104±11†

76±10

70±6

104±6†

109±7†

82±12

115±7†

ID

54±5

46±6

50±5

51±6

49±4

53±4

52±4

51±5

53±5

VRBC

35±6

24±4

34±6

25±5

27±4

35±4

36±4

27±4

36±4

Q

50±5

25±4*

42±4†

32±6

32±4

48±5†

48±5†

33±5

50±6†

ID

37±5

32±4

33±5

38±5

37±4

38±4

38±4

37±5

38±4

VRBC

35±5

20±5

30±5

24±4

23±3

32±4

33±5

24±5

36±5

Q

24±3

10±3*

16±3

17±3

15±3

23±3†

23±4†

16±4

26±4†
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FIGURE LEGENDS
Figure 1. Schematic representation of an arteriolar bifurcation used for study. Presented are the key
measured parameters of arteriolar diameter and erythrocyte velocity, which are used to calculate blood flow
two daughter arterioles arising from a parent. Please see text for additional details.

Figure 2.

-2A (Panels

A and B, respectively) and 3A-4A (Panels C and D, respectively) arteriolar bifurcations in LZR and OZR
u
minute collection window. Please see text for additional details.

Figure 3.

-2A arteriolar bifurcations of LZR (Panel A) and OZR (Panel B) over the 5

minute collection period. Data (presented as mean±SE) are presented for LZR and OZR under control
conditions and in OZR following treatment of the cremaster muscle with phentolamine (Phent), TEMPOL
(TEM), SQ-29548, or combinations of these agents. * p<0.05 versus control in that strain. † p<0.05
versus LZR Control.

Figure 4.

-2A

arteriolar bifurcations in LZR and OZR. Data (presented as mean±SE) are presented for LZR and OZR
under control conditions and in OZR following treatment of the cremaster muscle with phentolamine
(Phent), TEMPOL (TEM), SQsummated either as differences between successive time points (Panels A and B) or as the absolute
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differences between successive time points (Panels C and D). * p<0.05 versus control in that strain. †
p<0.05 versus LZR control. Please see text for additional details.

Figure 5. The averag

-4A arteriolar bifurcations of LZR (Panel A) and OZR (Panel B) over the 5

minute collection period. Data (presented as mean±SE) are presented for LZR and OZR under control
conditions and in OZR following treatment of the cremaster muscle with phentolamine (Phent), TEMPOL
(TEM), SQ-29548, or combinations of these agents. * p<0.05 versus control in that strain. † p<0.05
versus LZR Control.

Figure 6.

-4A

arteriolar bifurcations in LZR and OZR. Data (presented as mean±SE) are presented for LZR and OZR
under control conditions and in OZR following treatment of the cremaster muscle with phentolamine
(Phent), TEMPOL (TEM), SQ-29548, or combinations of these agents.
summated either as differences between successive time points (Panels A and B) or as the absolute
differences between successive time points (Panels C and D). * p<0.05 versus control in that strain. †
p<0.05 versus LZR control. Please see text for additional details.

Figure 7.
arteriolar bifurcations of LZR and OZR in response to increasing concentrations of adenosine.

Data

(presented as mean±SE) are presented for 1Aata for 3A-4A
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as absolute differences (Panel D). * p<0.05 versus LZR under that condition. † p<0.05 versus LZR
control.

Figure 8.

tive,

absolute) at 1A-2A (Panel A) and 3A-4A (Panel B) bifurcations in OZR. Normal activity is defined as that
determined in arteriolar bifurcations at those two sites in LZR. Data (presented as mean±SE) are presented
for OZR following treatment of the cremaster muscle with phentolamine (Phent), TEMPOL (TEM), SQ29548, or combinations of these agents. * p<0.05 versus no change under that condition.

Figure 9. Presentation of the attractor describing the overall spatial-

-2A

arteriolar bifurcations in LZR (blue) and OZR (red) under control conditions (Panel A). The attractors are

points within that condition. In subsequent panels, the control data is greyed (light for LZR, dark for
OZR) and the effects of the interventions on the attractor are presented in black. This is done for
treatment with phentolamine (Panel B), TEMPOL and/or SQ-29548 (Panel C) and phentolamine and
TEMPOL and/or SQ-29548 (Panel D).

Figure 10. Presentation of the attractor describing the overall spatial-

-4A

arteriolar bifurcations in LZR (blue) and OZR (red) under control conditions (Panel A). The attractors are
presented as
points within that condition. In subsequent panels, the control data is greyed (light for LZR, dark for
OZR) and the effects of the interventions on the attractor are presented in black. This is done for
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treatment with phentolamine (Panel B), TEMPOL and/or SQ-29548 (Panel C) and phentolamine and
TEMPOL and/or SQ-29548 (Panel D).

Figure 11. Presentation of the attractor describing the overall spatial-temporal behav

-2A

(Panel A) and 3A-4A (Panel B) arteriolar bifurcations in LZR and OZR under control conditions and in
response to treatment with 10-3M adenosine. As described in Figures 9 and 10, the control data is greyed
(light for LZR, dark for OZR) a
OZR are presented in black.
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Conceptual Framework
The fourth chapter is entitled “Blunted Temporal Activity of Microvascular Perfusion
Heterogeneity in Metabolic Syndrome: A New Attractor for Peripheral Vascular Disease?”. It addresses
what we hypothesized would be the logical compensation for the increase in perfusion heterogeneity at
bifurcations seen in the previous paper, what is known as “temporal switching”. The perfusion
heterogeneity at bifurcations is iterated longitudinally across the entire microvascular network and should
lead to local regions of tissue with an accelerated buildup of metabolic dilators, thus increasing the
temporal switching at bifurcations to meet that demand. Interestingly, the temporal activity was blunted in
both the proximal and distal microcirculation. This suggests that the poor muscle performance in the OZR
is the cumulative response of spatial and temporal impairments to blood flow regulation.
Of special relevance is the identification of an attractor for PVD, which is elucidated by the
presentation of the temporal data as an iterated map. Beyond a scientific curiosity, an attractor is
significant because it describes how a dynamic system will evolve toward a set of conditions over time.
The attractor generated for a system demonstrates the ability of the system to respond to perturbations,
and can infer the flexibility of a network as the system will seek to return to its attractor upon being
disturbed. The attractor for the LZR, representing health, has a wide range and is centered on 0.5. This
remains constant for both the proximal and distal microcirculation. The attractor for the OZR is not only
elevated throughout the entire microcirculation, but also significantly limited in its range, suggesting that
the system is limited in its ability to respond to perturbations. This compromised network flexibility
could be a major contributor to the development of poor vascular outcomes in MetSyn subjects.
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Chapter 5
Altered Hemodynamics within the Skeletal Muscle Microvasculature in the Obese Zucker Rats
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ABSTRACT
Increasing evidence has indicated that a key contributor to the development, maintenance, and
progression of peripheral vascular disease (PVD) is altered microvascular structure, function, and
reactivity. Recent research has observed an increasingly heterogeneous perfusion distribution within the
skeletal muscle microvasculature of the obese Zucker rat, a model of PVD. This heterogeneous perfusion
distribution is iterated throughout the microvascular network and dominated by spatially distinct
mechanisms; driven by alpha-adrenergic dysfunction in proximal microvessels and oxidant stress based
increases in vascular thromboxane A2 in distal microvessels. Additional research demonstrated that a
temporal compensation for the increased heterogeneous perfusion distribution was also blunted. Taken
together, the spatial and temporal alterations to microvascular blood flow will serve to entrench a
physiological state of inadequate blood flow regulation throughout skeletal muscle. One of the hallmark
characteristics of PVD is an inability to resist the development of fatigue. The heterogeneous perfusion
distribution within the microvasculature suggests that the OZR’s inability to resist fatigue may be the
result of a dysfunctional distribution of erythrocytes in the skeletal muscle microcirculation. To determine
erythrocyte distribution with the capillaries and arterioles we utilized the in situ cremaster preparation
with video microscopy to obtain a representative sample of capillary tube hematocrit and the blood
perfused isolated hindlimb preparation with I125 labeled albumin and Cr51 labeled RBCs to obtain
microvascular hematocrit. The analysis indicates that the cumulative sum of altered spatial and temporal
regulation of microvascular perfusion distribution results in a lowered microvascular hematocrit and a
large variation in capillary hematocrit in the OZR compared to the LZR. This altered erythrocyte
distribution represents a significant contributor to the poor muscle performance observed in the OZR.
Key Words: microcirculation; microvascular hematocrit; obese zucker rat; peripheral vascular disease;
microvascular dysfunction; network hemodynamics
INTRODUCTION
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PVD is an insidious pathologic state that ultimately deprives organs of adequate blood flow and afflicts
between 8-13 million Americans. The prevalence of PVD increases with age, afflicting 10-20% of the
population over 60 years of age. Once diagnosed, PVD is largely irreversible barring surgery, and
possesses a high direct and indirect cost burden to society29, 30 . A growing subset of the population
presents with the overt signs of PVD, but without the classically demonstrated atherosclerotic lesions,
suggesting that a significant contributor to the development of PVD is microvascular dysfunction.
Human subjects diagnosed with the Metabolic Syndrome (MetSyn) possess a significantly greater
risk of developing PVD. The significance of this cannot be understated, as ~34% of the U.S. meet the
diagnosable criteria for MetSyn today29, 31-34. The rate of the overweight, obese, and extremely obese
adults within the U.S. population is over 75%35. Given that obesity is generally understood to be the
initiating condition for the development of MetSyn, there is concern that a significant portion of the
population is at risk for developing MetSyn and the associated pathologies at a much younger age.
The obese Zucker rat (OZR) is a rodent model for studying the development of MetSyn. Owing
to its dysfunctional leptin receptor the OZR possesses an impaired satiety reflex, which results in chronic
hyperphagia. Thus, by ≈17 weeks of age, the OZR experiences significant increases in mass, moderate
hypertension, insulin resistance, loss of glycemic control, and a pro-inflammatory and pro-thrombotic
state. The OZR is an appropriate model for examining the development of MetSyn and nonatherosclerotic PVD. Recent studies have demonstrated that MetSyn in the OZR results in a progressive
decay of skeletal muscle performance36, 37. There appears to be dual contributors to this inability of
skeletal muscle to resist fatigue. One of the contributors appears to be alpha-adrenergic in origin and
restricts bulk blood flow delivery to the skeletal muscle. Another contributor is impaired oxygen uptake,
resulting from an increase in oxidant stress, which reduces NO bioavailability as well as altering
arachidonic acid metabolism to increase vascular production of thromboxane A2 (TxA2). The
simultaneous treatment of both altered systems results in improved performance outcomes in the OZR.
Additional studies concluded that the above mentioned contributors to impaired skeletal muscle
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performance impact the microcirculatory system in a spatially distinct manner. The dysfunction in the
proximal microcirculation is dominated by altered alpha-adrenergic based elements to vascular tone,
while the dysfunction within the distal microcirculation is characterized by endothelial dysfunction,
specifically via altered metabolism of arachidonic acid (AA)38, 39. However, both serve to increase
perfusion heterogeneity at bifurcations in the microvasculature. The interpretation of the above work
suggests PVD promotes perfusion heterogeneity at microvascular bifurcations through spatially distinct
mechanisms40, 41. Further research postulated that, due to the increased perfusion heterogeneity at
bifurcations, temporal switching between the low flow and high flow branch would increase due to
accelerated buildup of metabolites, or other regulatory signals, downstream within the low flow pathway.
However, our most recent data suggested that temporal switching is actually blunted at bifurcations in the
OZR40, 41. The cumulative outcome of increased perfusion heterogeneity across a microvascular network,
along with simultaneous blunting of the temporal switching, will entrench the impairments to perfusion
distribution and mass transport/exchange, ultimately contributing to negative outcomes for skeletal
muscle performance. Our hypothesis, building on the above work, is that the Metabolic Syndrome
entrenches alterations to blood flow distribution and negatively impacts erythrocyte distribution
throughout the microvasculature. Specifically, we hypothesize that the alterations to perfusion distribution
in the OZR, when iterated throughout the entire skeletal muscle network, will serve to lower average
microvascular hematocrit and thus result in impaired oxygen delivery within the capillaries.
We predict that hematocrit in the skeletal muscle microcirculation of the OZR will be
significantly lower across the whole organ compared to the LZR. This overall reduction of hematocrit
would occur in the OZR due to a heterogeneous perfusion distribution that would skew the hematocrit
disproportionally low compared to flow distribution. The primary goal of the experiment is to obtain
microvascular hematocrit (Hmv) using the Overholser model, as previously described42. Additionally,
capillary tube hematocrit will be obtained in a representative sample to determine the impact of an altered
flow distribution on oxygen exchange vessels. The inability of the skeletal muscle microcirculation to
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adequately regulate perfusion distribution becomes progressively more relevant as increased metabolic
demand cannot be matched with increased perfusion. At rest, the lowered average hematocrit may have
little impact on tissue oxygenation, but with increased metabolic demand this would result in an
inadequate supply of oxygen to tissue. This would offer insight into the acceleration in fatigue resistance,
and also into the increased inflammatory state often observed in the MetSyn, which may be due to the
tissue hypoxia.
MATERIALS AND METHODS
Approximately 17 week old male lean and obese Zucker rats (Harlan) were used. All protocols
have prior approval of the IACUC, the rats will be housed within the animal quarters of WVU, and
provided with sterilized food and water ad libitum. All animals were anesthetized with sodium
pentobarbital (390mg/mL), and a patent airway maintained with tracheal intubation. At the conclusion of
the experiment, all animals are humanely euthanized with excess sodium pentobarbital and a bilateral
pneumothoractomy.
Isolated Hind Limb preparation and Tracer Washout Curves - In a set of age matched animals, the selfperfused left hindlimb of each animal will be isolated in situ, as demonstrated previously43. The carotid
artery will be cannulated for monitoring of mean arterial pressure and the jugular vein cannulated for
infusion of heparin (500IU/kg) to prevent coagulation of the blood. An angiocatheter will be inserted into
the femoral artery for insertion of each bolus tracer. A Transonic probe (0.5-0.7 PS) of the appropriate
size will be placed on the femoral artery to monitor perfusion. A small shunt will be placed in the femoral
vein of the gastrocnemius muscle to facilitate sampling of the venous effluent. The above referenced
interventions, phentolamine (10 mg/kg), TEMPOL (50 mg/kg) and/or SQ-29548 (10 mg/kg), will be
intravenously introduced to the animal and tested for efficacy using phenylephrine (10 μg/kg),
methacholine (10 μg/kg) or U-46619 (10 μg/kg), respectively. Two radionuclides will be utilized, I125
labeled albumin and Cr51 bound to red blood cells. Upon bolus injection, the venous effluent will be
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collected at a rate of 1/s for the subsequent 35 seconds. The subsequent injection, after each intervention,
did not occur until 30 minutes of perfusion with an injection of homologous erythrocytes used to replace
the lost hematocrit. They were examined for estimated microvascular hematocrit (Hmv). All were prepared
using published protocols42, 44-48.
Preparation of In Situ Cremaster Muscle: In a separate set of age matched animals the cremaster muscle
was separated from surrounding tissues and isolated for viewing with intravital microscopy. During the
entire experiment the cremaster was maintained at 35oC, superfused with a physiological salt solution and
bubbled with a 5% CO2/balance N2 gas. Capillaries with red blood cell flow were identified using on
screen video microscopy and hematocrit was quantified at 10 vessels per animal. All procedures were
performed under control conditions in LZR and OZR, and the following interventions were added to the
superfusate; the anti-oxidant TEMPOL (10-3 M), the TxA2 receptor antagonist SQ-29548 (10-4 M), and/or
the alpha1/alpha2 adrenergic receptor antagonist phentolamine (10-5 M).
Data Analysis
For the tracer washout analysis, the following equations were used from Overholser et al. to
obtain the hematocrit reduction ratio (hr)42. The hematocrit reduction ratio is the ratio of the
microvascular hematocrit to the large vessel hematocrit and is calculated from the equation below.
C l.organ (t-T) = hr C R.organ [(t-T)hr)
where C l.organ is the albumin tracer curve, C R.organ is the red cell tracer curve, t is time, and T is the mean
transit time. This will allow deduction of the microvascular hematocrit reduction ratio. The hr can be
entered into the following equation to calculate microvascular hematocrit.
Hr = Hmv/ Hlv where Hmv is microvascular hematocrit and Hlv is large vessel hematocrit.
Capillary tube hematocrit was calculated from video stills utilizing the in situ cremaster
preparation, as described previously40, 41. It was calculated by counting the number of red blood cells in a

170

known length and diameter of vasculature. All data is presented as mean ± SEM with statistically
significant differences represented by p<0.05. Student’s t-test or analysis of variance (ANOVA) with
Student-Newman-Keuls post-hoc test was used as needed.
RESULTS
Table 1 contains baseline characteristics of the lean and obese Zucker rats used in the indicator
dilution washout study. Compared to the LZR controls, at ≈17 weeks of age the OZR model exhibits
significantly increased mass, moderate increases in mean arterial pressure, insulin resistance,
dyslipidemia, and elevated plasma glucose levels.
Table 1: Indicator Dilution
Washout
Mass (grams)
MAP

LZR

OZR

361 ± 9
102 ± 4

688 ± 12
138 ± 10

Figure 1 is a representative figure containing the washout data for I-125 labeled albumin and Cr-51
labeled RBCs in both the OZR and LZR. The solid red and black lines are the LZR albumin and RBC
tracers respectively. The dotted red and black lines are the OZR albumin and RBC tracers respectively. It
is evident that the OZR RBC’s initially washout more rapidly than the LZR RBC’s, but then slow at the
end of the time period. The OZR albumin curve has a smaller height but a much higher tail than the LZR
control.
Figure 2 presents the microvascular hematocrit as calculated from the ratio between the animal’s
respective albumin and RBC tracer washout curves. It shows that the LZR (n=5) microvascular
hematocrit remains similar to the average large vessel hematocrit of 45. The OZR (n=8) microvascular
hematocrit is significantly lower than the LZR control. The microvascular hematocrits of the OZR with
interventions of phentolamine or TEMPOL/SQ-29548 appear lower but have very large SEM. The
microvascular hematocrit of the OZR with all treatments is significantly elevated above the OZR
baseline. * p < 0.05 vs. LZR. † p < 0.05 vs. OZR.
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Figure 3 is the capillary tube hematocrit as calculated from video microscopy. There were no
significant differences between LZR, OZR, and OZR with treatments. * p < 0.05 vs. LZR. † < 0.05 OZR.
Discussion
The culmination of recent work has shown that alterations within the skeletal muscle
microcirculation of the obese Zucker rat result in increasingly heterogeneous perfusion distributions at
bifurcations. Specifically, there is an increased perfusion distribution in the OZR with spatially distinct
mechanisms that is unable to be compensated for temporally. This results in a ‘low flow” and “high flow”
pathway at bifurcations that is iterated across the microcirculatory network. This inability to adequately
distribute blood flow will have a negative impact on erythrocyte distribution, with the bulk of RBC’s
flowing down the “high flow” pathway and being unable to redistribute to the “low flow” pathway with
increased metabolic demand. The importance of distribution of erythrocytes lies within three basic
concepts of erythrocyte distribution within blood flow. The first is the Fahraeus effect, which is a lowered
tube hematocrit caused by the differential velocities of RBC’s and plasma. The second is the Fahraeus
network effect, which describes how an unequal hematocrit distribution at a proximal bifurcation will
lead to increasingly heterogeneous hematocrit distribution further downstream and result in an averaged
lower hematocrit. The final concept is phase separation, which describes how low flow branches or side
branches may “skim” the RBC poor areas of the blood, again leading to lowered hematocrit in those side
branches relative to the high flow49. The integration of all three concepts, when combined with the
evidence of increased perfusion distribution heterogeneity in the OZR, suggests that this will lead to an
overall reduction in microvascular hematocrit as well as capillary tube hematocrit.
The results of the indicator dilution tracer washout experiment show that there is a
reduction in OZR microvascular hematocrit compared to the LZR. The treatments of phentolamine and
TEMPOL/SQ-29548 by themselves demonstrate not necessarily a significant increase in hematocrit
distribution, but certainly a large increase in the variance that removes any significance compared to the
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LZR. However, treatment with all of the interventions in the OZR does significantly improve
microvascular hematocrit compared to the LZR.
The capillary tube hematocrit does not show a significant difference between the LZR and OZR,
or with any of the OZR interventional groups. However, what is readily apparent is the large variance
observed in the OZR compared to any other group, LZR, OZR, or OZR + intervention. This indicates that
there is indeed significant high and low hematocrit levels within the gas exchange vessels of the OZR,
heterogeneity not observed in the LZR. The inability of this technique to obtain the lower hematocrit
levels hypothesized may in fact be a limitation of the preparation itself, whereby vessels are chosen that
have steady visible RBC flow, resulting in an inadequate sample size representative of the population.
The conclusion of the above research is that there is a lowered average hematocrit within the
OZR microcirculation. It is a result of the entrenched heterogeneous perfusion distribution observed at
bifurcations within the OZR, and not only serves as a significant contributor to the impaired performance
of skeletal muscle, but most likely would result in development of ischemic or pro-inflammatory regions
of tissue where the low distribution of erythrocytes exists. While the hematocrit within the capillaries
does not initially show the differences hypothesized, the increased variance would indicate areas of
significantly elevated and lowered hematocrit compared to the LZR, suggesting that perhaps our sample
population is not representative of the whole tissue bed.
Taken together with our previous research, the outcome of this lowered microvascular hematocrit
and increase in variance within the capillaries allows for a better understanding of the progressive decay
of skeletal muscle function within MetSyn. Increasing evidence points toward altered regulation of
microvascular control, largely influenced by alpha adrenergic dysfunction and oxidant stress based
increases in thromboxane A2, as a significant contributor to this dysfunction. This results in an inability of
the peripheral vascular system to adequately deliver oxygen to the appropriate local tissue region.
Speculatively, this has tremendous impact on the human population of MetSyn, including those already
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diagnosed with PVD. Those diagnosed with PVD will be best served with not just exercise, but also
treatment of the underlying microvascular problems. Further, as the epidemic of MetSyn and PVD
increases within developed countries, the subpopulation of subject presenting without atherosclerotic
plagues and lesions will require alternative diagnostic exams, as well as treatment of the microvascular
disease.
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Figure Legends
Figure 1: Representative figure of tracer washout curves. Presented are the I-125 labeled albumin (red
lines) and the Cr-51 red blood cells (black lines). The LZR lines are solid and the OZR lines are dashed.
The microvascular hematocrit is calculated as the ratio between the two lines using Overholser et al.
Figure 2: Bar chart showing the microvascular hematocrit as calculated from tracer washout curves of
LZR, OZR, and OZR + interventions. Data is resented as mean ± SEM. * p < 0.05 vs. LZR. † p < 0.05 vs.
OZR.
Figure 3: Bar chart showing capillary tube hematocrit as calculated from video stills for the LZR, OZR,
and OZR ± interventions. Data is presented as mean ± SEM. * p < 0.05 vs. LZR. † p < 0.05 vs. OZR.
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Conceptual Framework
The fifth and final chapter focused on the hemodynamics within a microvasculature network, and whether
the spatial and temporal alterations to vascular tone in the Obese Zucker rat have an impact on
microvascular hematocrit. It sought to integrate the previous work and determine whether there is an
altered erythrocyte distribution throughout the microvascular and capillary networks. We found a
significantly lowered microvascular hematocrit in the OZR and a large variation in capillary hematocrit
compared to the healthy LZR. These results suggest that MetSyn induced alterations to vascular tone
ultimately lead to a lowered erythrocyte distribution, and provide insight into the perfusion:demand
mismatch and lowered performance outcomes observed in the OZR.
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Discussion
The purpose of this dissertation is to investigate network control of blood flow to determine the
extent to which Metabolic Syndrome-induced microvascular dysfunction alters hemodynamics within
skeletal muscle. We first sought to determine if MetSyn impacts the ability of isolated microvessels to
integrate multiple inputs and subsequently change overall diameter compared to a healthy animal. Myogenic
activity is a significant contributor to vascular tone and significantly elevated vasoconstriction in response to
elevated intraluminal pressure is observed in the OZR in compared to the LZR. The first chapter emphasized
that MetSyn alters myogenic activity largely through increases in oxidant stress, which has the combined
effect of reducing nitric oxide bioavailability and altering AA metabolism to increase production of vascular
TxA2. The data demonstrated that the oxidant stress derived changes to myogenic activation has a significant
effect in blunting the responses of dilator stimuli. The blunted dilator response occurs in hypoxia, a dilation
derived from endothelial dependent NO production, and dilation to a mimic of metabolic stimulation.
Interestingly, the skeletal muscle microvasculature in the OZR shows an equal impact of an antioxidant or
TxA2 receptor antagonist at alleviating the blunted dilator response to hypoxia. In contrast, while there is a
comparable blunted dilator response to acetylcholine, TEMPOL proved to be a far more effective
intervention than SQ-29548. While treatment with adenosine (mimic for metabolic demand) showed a less
severe blunting of dilation when integrated with pressure induced constriction, it still was lower, suggesting
that the increased myogenic activation could play a role in altering blood flow despite increases in metabolic
demand. Taken together, these data implicate oxidant stress and vascular production of TxA2 as significant
contributors to the increased myogenic activation seen in the OZR and serves to alter basal vascular tone and
hemodynamics within the confines of MetSyn. This is part of the foundational work that illustrates ex vivo
that MetSyn does not just alter point sources for reactivity in blood vessels, but fundamentally alters the
ability of the network to appropriately integrate dilator and constrictor signals.
Building on this work, the second chapter demonstrates a functional performance inhibition within
the OZR skeletal muscle. The OZR has significantly blunted blood flow, higher resistance, decreased oxygen
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uptake, and decreased oxygen exchange compared to the LZR. These combined factors serve to significantly
impair the OZR’s ability to resist fatigue development at all levels of metabolic stimulus and are present even
at rest. It was determined that the restricted bulk blood flow and increased resistance present in the OZR are
alleviated with treatment of phentolamine, an alpha-adrenergic antagonist. The blunted oxygen extraction and
oxygen uptake were alleviated with TEMPOL or SQ-29548. There were two key observations about these
data. The first is that no treatment by itself improved tension development in the OZR compared to the LZR.
This suggests a dual component of dysfunction that will equally serve to limit OZR skeletal muscle
performance, and both components must be addressed for an effective outcome in terms of functional
performance. The second observation is the decreased oxygen extraction and oxygen uptake in the OZR
skeletal muscle. Classically it would be expected that by repairing the blunted bulk blood flow delivery
within the muscle this would allow for adequate oxygen delivery throughout the skeletal muscle.
Additionally, it would be expected that there would be an increased oxygen extraction as a compensatory
mechanism for the decreased blood flow and previously identified rarefaction present in the OZR. This
implies two spatially distinct mechanisms within the vasculature, an alpha-adrenergic constraint prohibiting
bulk blood flow and dysfunction in the gas exchange regions of the vasculature dominated by increasing
oxidant stress. This would provide the impetus for Chapter 3, where we begin to examine the perfusion
distributions throughout the microvascular network.
Chapter 3 begins by changing the preparation to the in situ cremaster preparation, a preparation that
allows us to examine an intact skeletal muscle microvascular network. The preparation allowed us to
combine video microscopy with an optical Doppler velocimeter, thus enabling calculation of the blood
flow distribution at bifurcations of varying sizes. A heterogeneous blood flow distribution was observed
in the OZR microvascular network, meaning that a “high flow” and “low flow” pathway at each
bifurcation was iterated throughout the entire network. Interestingly, the data revealed spatially distinct
mechanisms, with alpha-adrenergic dysfunction dominating the proximal microcirculation and oxidant
stress based increases in vascular TxA2 playing a greater role in the distal microcirculation. The

183

respective interventions were able to restore perfusion distributions back to levels of control at each
spatially distinct location. This was further supported by an I125 labeled albumin washout curve, which
utilized the isolated gastrocnemius preparation. It is representative of whole network flow distribution,
and the OZR washout kinetics clearly revealed altered intravascular flow patterns compared to the LZR,
which was further confirmed with a computation model demonstrating the expected heterogeneous flow
distribution throughout the OZR microvasculature and predicting a large number of very low flow
ischemic pathways with only a few high throughput pathways.
The results of the previous study indicating a heterogeneous perfusion distribution with spatially
distinct mechanisms in the skeletal muscle microvasculature of the OZR lead us to ask how the body
would normally compensate for such dysfunction. When one examines the functional impact of a
“high/low” flow pathway in microvascular skeletal muscle, one would expect to a see buildup of waste
products and ischemic metabolites downstream of the low flow pathway, as predicted computationally.
This would occur naturally even in health, as even the LZR does not have a perfect 50/50 flow
distribution pattern. Due to the increase in perfusion distribution heterogeneity in the OZR, one would
expect a more severe ischemia within the low flow pathway, thus providing an elevated rate of buildup of
metabolically active waste products that would have a dilatory effect upon the low flow pathway. Thus
the “high/low” flow pathway would switch, and we hypothesized that in the OZR there would be a
significantly increased temporal switching compared to the LZR. However, the temporal switching was
blunted in the OZR in both the proximal and distal microcirculation. The importance of blunted temporal
switching cannot be understated. Not only is there no temporal compensation for the perfusion
heterogeneity in skeletal muscle, but it is actually blunted. This implies that it will exacerbate the
perfusion heterogeneity, locking in a high and low flow pathway, resulting in chronic ischemic regions of
tissue at rest and permanently inhibiting blood flow regulation. Additionally, the temporal aspect of the
data allowed for the generation of an attractor for the OZR and LZR. An attractor is a set of conditions
that a dynamic system will adhere to over time. In the LZR, attractor centers on 0.5, but has a broad and
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diverse range. This illustrates the constant flux that persists at homeostasis. Systems must be perturbed at
multiple levels to alter attractors, and this is clearly illustrated in the OZR. The attractor for the OZR was
elevated and reduced in range compared to the LZR. This suggests a limited ability of the OZR
microvascular network to respond adequately to perturbations. The cumulative outcome of spatial and
temporal alterations to skeletal muscle microvasculature is to produce an inability of the system to
adequately regulate blood flow. This evidence, combined with previously referenced papers, suggest that
this altered perfusion distribution will have an effect on erythrocyte distribution throughout the system,
and brought us to Chapter 5.
Chapter 5 hypothesizes that the altered perfusion distribution iterated across the microvascular
network, combined with an inability to temporally compensate, will result in a lowered microvascular
hematocrit as well as a lowered capillary hematocrit. It utilizes indicator dilution washout curves to obtain
a “snapshot” of microvascular hematocrit as well as video microscopy to obtain a representative sample
of capillary hematocrit. The results showed that the OZR showed a significant decrease in microvascular
hematocrit. Treatment with either an alpha-adrenergic blocker, antioxidant, or TxA2 receptor antagonist
improved the variance of the OZR, but only with all three was there a significant improvement of
hematocrit with equal variance to even above levels of control. The capillary hematocrit proved slightly
troublesome, as it indicated no significant differences between any groups, LZR or OZR. However, the
variance of the OZR indicates very high and low flow hematocrits, which when averaged are not
significantly different. This would indicate that our hypothesis is correct, and perhaps our sample is not
representative of the true population.
To summarize the above dissertation, the evidence presented suggests that MetSyn contributes to
dysfunctional vascular control through increased myogenic activation, which is brought on by oxidant
stress based increases in vascular production of TxA2. This, combined with adrenergic dysfunction,
results in significant impairments to the ability of skeletal muscle to resist fatigue. Subsequent research
demonstrates that a primary consequence of alterations to vascular tone is increased perfusion
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heterogeneity at bifurcations, and that this perfusion heterogeneity exists at both the proximal and distal
microcirculation. The mechanisms of this dysfunction are spatially distinct, with adrenergic dysfunction
dominating at the proximal microcirculation and increases in oxidant stress and alterations to arachidonic
acid metabolism dominating in the distal microcirculation. Further, MetSyn blunts the temporal switching
that potentially could alleviate the increased perfusion distribution. The cumulative outcome of spatial
and temporal alterations to vascular tone is a lower microvascular hematocrit, which could serve as a
influential contributor to the inability of the OZR skeletal muscle to resist fatigue development.
MetSyn entrenches a pathological condition whereby the skeletal muscle circulation is limited not
only in matching perfusion with demand, but also restricts the logical compensation through temporal
switching. This inevitably leads to the condition whereby a subject is unable to reverse the decreased
performance outcome, and we argue that it is at this point where PVD, CVD, and the other pathologies
intrinsically indicated by MetSyn begin to present. Further studies are needed to examine the impact of
common interventions on microvascular function. These include but are not limited to exercise, weight
loss, surgery, lifestyle alterations, and pharmaceutical drugs. Each needs to be evaluated for its impact on
the underlying microvascular dysfunction. Taken together, this dissertation hopefully sheds light on the
mechanisms within the microcirculation that MetSyn and PVD impact, and allows for novel and relevant
treatment for the human population.
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